<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for fatigue in Parkinson's disease - Elbers, RG - 2015 | Cochrane Library</title> <meta content="Interventions for fatigue in Parkinson's disease - Elbers, RG - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010925.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for fatigue in Parkinson's disease - Elbers, RG - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010925.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010925.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for fatigue in Parkinson's disease" name="citation_title"/> <meta content="Roy G Elbers" name="citation_author"/> <meta content="elbers.r@hsleiden.nl" name="citation_author_email"/> <meta content="John Verhoef" name="citation_author"/> <meta content="Faculty of Health, University of Applied Sciences Leiden" name="citation_author_institution"/> <meta content="Erwin EH van Wegen" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Henk W Berendse" name="citation_author"/> <meta content="Neuroscience Campus Amsterdam, VU University Medical Center" name="citation_author_institution"/> <meta content="Gert Kwakkel" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010925.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/10/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010925.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010925.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010925.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Exercise; Central Nervous System Stimulants [*therapeutic use]; Dopamine Agents [*therapeutic use]; Fatigue [etiology, *therapy]; Parkinson Disease [*complications]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010925.pub2&amp;doi=10.1002/14651858.CD010925.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010925\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010925\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","pl","fr","ta","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010925.pub2",title:"Interventions for fatigue in Parkinson\u0027s disease",firstPublishedDate:"Oct 8, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Movement Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010925.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010925.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010925.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010925.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010925.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010925.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010925.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010925.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010925.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010925.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7642 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010925.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0031"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0032"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/appendices#CD010925-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/table_n/CD010925StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/table_n/CD010925StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for fatigue in Parkinson's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#CD010925-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Roy G Elbers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#CD010925-cr-0003">John Verhoef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#CD010925-cr-0004">Erwin EH van Wegen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#CD010925-cr-0005">Henk W Berendse</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information#CD010925-cr-0006">Gert Kwakkel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information/en#CD010925-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 October 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010925.pub2">https://doi.org/10.1002/14651858.CD010925.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010925-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010925-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010925-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010925-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010925-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010925-abs-0001" lang="en"> <section id="CD010925-sec-0001"> <h3 class="title" id="CD010925-sec-0001">Background</h3> <p>Factors contributing to subjective fatigue in people with idiopathic Parkinson’s disease (PD) are not well known. This makes it difficult to manage fatigue effectively in PD. </p> </section> <section id="CD010925-sec-0002"> <h3 class="title" id="CD010925-sec-0002">Objectives</h3> <p>To evaluate the effects of pharmacological and non‐pharmacological interventions, compared to an inactive control intervention, on subjective fatigue in people with PD. </p> </section> <section id="CD010925-sec-0003"> <h3 class="title" id="CD010925-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>); MEDLINE (via PubMed); Ovid EMBASE; EBSCO CINAHL; Ovid PsycINFO; PEDro; and the WHO International Clinical Trials Registry Platform Search Portal up to April 2015. References of included studies and identified review articles were screened for additional studies. There were no restrictions based on language, date of publication or study setting. </p> </section> <section id="CD010925-sec-0004"> <h3 class="title" id="CD010925-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that report on subjective fatigue in people with PD. </p> </section> <section id="CD010925-sec-0005"> <h3 class="title" id="CD010925-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed study selection, data collection and risk of bias assessments. </p> </section> <section id="CD010925-sec-0006"> <h3 class="title" id="CD010925-sec-0006">Main results</h3> <p>Eleven studies were eligible for this systematic review, with a total of 1817 people. Three studies included only people who experienced clinically relevant fatigue (Fatigue Severity Scale score ≥ 4 out of 7 or Multidimensional Fatigue Inventory total score &gt; 48 out of 100), whereas all other studies did not select participants on the basis of experienced fatigue. Nine studies investigated the effects of medication (i.e. levodopa‐carbidopa, memantine, rasagiline, caffeine, methylphenidate, modafinil or doxepin) on subjective fatigue. All studies were placebo controlled. There was insufficient evidence to determine the effect of doxepin on the impact of fatigue on activities in daily life (ADL) or fatigue severity (one study, N = 12, standardised mean difference (SMD) = ‐1.50, 95% confidence interval (CI) ‐2.84 to ‐0.15; low quality evidence). We found high quality evidence that rasagiline reduced or slowed down the progression of physical aspects of fatigue (one study, N = 1176, SMD = ‐0.27, 95% CI ‐0.39 to ‐0.16, I<sup>2</sup> = 0%). None of the other pharmacological interventions affected subjective fatigue in PD. With regard to adverse effects, only levodopa‐carbidopa showed an increase for the risk of nausea (one study, N = 361, risk ratio (RR) = 1.85, 95% CI 1.05 to 3.27; high quality evidence). Two studies investigated the effect of exercise on fatigue compared with usual care. We found low quality evidence for the effect of exercise on reducing the impact of fatigue on ADL or fatigue severity (two studies, N = 57, SMD = ‐0.45, 95% CI ‐1.21 to 0.32, I<sup>2</sup> = 44%). </p> </section> <section id="CD010925-sec-0007"> <h3 class="title" id="CD010925-sec-0007">Authors' conclusions</h3> <p>Based on the current evidence, no clear recommendations for the treatment of subjective fatigue in PD can be provided. Doxepin may reduce the impact of fatigue on ADL and fatigue severity; however, this finding has to be confirmed in high quality studies. Rasagiline may be effective in reducing levels of physical fatigue in PD. No evidence was found for the effectiveness of levodopa‐carbidopa, memantine, caffeine, methylphenidate, modafinil or exercise. Studies are needed to investigate the effect of exercise intensity on exercise capacity and subjective fatigue. Future studies should focus on interventions that address the maladaptive behavioural or cognitive aspects of fatigue in people with PD. Characteristics, such as severity and nature of perceived fatigue and underlying mood disorders should be considered to identify responders and non‐responders when studying interventions for fatigue. The development of a core‐set of self‐report fatigue questionnaires with established responsiveness and known minimal important difference values will facilitate the interpretation of change in fatigue scores. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010925-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010925-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010925-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010925-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010925-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010925-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010925-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010925-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010925-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ta#CD010925-abs-0009">தமிழ்</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010925-abs-0004" lang="en"> <h3>Treatment for fatigue in Parkinson's disease</h3> <p>At least one‐third of people with Parkinson's disease complain about fatigue. It is unclear what treatment is best to reduce fatigue in people with Parkinson's disease. </p> <p>We reviewed the medical literature up to April 2015, and found 11 studies that included a total of 1817 people. Nine studies investigated the effects of medication (i.e. levodopa‐carbidopa, memantine, rasagiline, caffeine, methylphenidate, modafinil or doxepin) on fatigue. Two studies investigated the effects of exercise on fatigue. We found no studies that investigated the effect of cognitive‐behavioural therapy. </p> <p>We found that doxepin (one study, 12 people, low quality evidence), a drug to treat depression, may reduce fatigue. We found that rasagiline (one study, 1176 people, high quality evidence), an anti‐Parkinson drug, reduced or slowed down the progression of physical fatigue. Most drugs were safe; however, levodopa‐carbidopa (one study, 361 people, high quality evidence) may cause nausea. </p> <p>We found no evidence that exercise (two studies, 57 people, low quality evidence) reduces fatigue in Parkinson's disease. </p> <p>Based on the current evidence, it is not clear what treatment is most effective to treat fatigue in people with Parkinson's disease. Future studies should investigate the effect of cognitive‐behavioural therapy on fatigue in people with Parkinson's disease. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010925-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010925-sec-0081"></div> <h3 class="title" id="CD010925-sec-0082">Implications for practice</h3> <section id="CD010925-sec-0082"> <p>The current evidence does not provide a reliable basis for deciding on treatment of subjective fatigue in people with PD. Doxepin may reduce the impact of fatigue on ADL and fatigue severity; however, this finding has to be confirmed in high quality studies. Rasagiline may be effective in reducing levels of physical fatigue in people with PD, whereas no evidence was found for the effectiveness of levodopa‐carbidopa, memantine, caffeine, methylphenidate, modafinil and exercise. As depressive disorders may modify the effect of interventions on subjective fatigue in people with PD, treatment of fatigue should always be accompanied by assessment and treatment of underlying depression. </p> </section> <h3 class="title" id="CD010925-sec-0083">Implications for research</h3> <section id="CD010925-sec-0083"> <p>The conclusions of this systematic review are based on studies that in general were characterised by small sample size. Future studies should increase sample size to reduce the probability of a type II error, that is concluding that the treatment is not effective when in reality it is. Studies are needed to investigate the effect of exercise intensity on exercise capacity and subjective fatigue. Future studies should concentrate on programmes that focus on the behavioural or cognitive aspects that address maladaptive behaviour or coping related to fatigue in people with PD. Patient characteristics, such as severity and characteristics of perceived fatigue and underlying mood disorders, should be considered to identify responders and non‐responders when studying interventions for fatigue. The development of a core‐set of self‐report fatigue questionnaires with established responsiveness and known MID values will facilitate the interpretation of change in fatigue scores in people with PD. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010925-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010925-sec-0029"></div> <div class="table" id="CD010925-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings levodopa‐carbidopa</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levodopa‐carbidopa compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinical, Northern America</b> </p> <p><b>Intervention: levodopa‐carbidopa</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>levodopa‐carbidopa</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean impact of fatigue and fatigue severity in the intervention group was 0.22 standard deviations lower (‐0.47 to 0.02). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>340 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours levodopa‐carbidopa.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>26 per 1000 (8 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.46</p> <p>(0.15 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does not increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect,post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>89 per 1000 (27 to 287)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.66</p> <p>(0.82 to 8.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000 (9 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00</p> <p>(0.28 to 3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does not increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>247 per 1000</p> <p>(140 to 436)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.85</p> <p>(1.05 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does increase risk for nausea.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings memantine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Memantine compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinical, Northern America</b> </p> <p><b>Intervention: memantine</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>memantine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.10 standard deviations higher (‐0.56 to 0.75). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000 (0 to 386)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does not increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000 (0 to 386)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does not increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000 (0 to 180)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00</p> <p>(0.13 to 69.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does increase risk for impulse control disorders.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>21 per 1000 (1 to 390)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.14</p> <p>(0.01 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does not increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean HRQOL in the intervention group was 0.38 standard deviations lower</p> <p>(‐0.29 to 1.04).<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours placebo.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> <p><sup>c</sup>Positive SMD (0.38) in results section indicates worse HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings rasagiline</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rasagiline compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinical, Europe and Northern America</b> </p> <p><b>Intervention: rasagiline</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>rasagiline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of physical fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of physical fatigue in the intervention group was 0.27 standard deviations lower (‐0.39 to ‐0.16). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, 2 independent comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours rasagiline.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000 (19 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.57</p> <p>(0.33 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for anxiety.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000 (31 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.80</p> <p>(0.50 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000 (10 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53</p> <p>(0.27 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 1000 (0 to 10)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.07</p> <p>(0.13 to 75.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for impulse control disorders.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 per 1000 (19 to 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.89</p> <p>(0.49 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000 (1 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.61</p> <p>(0.15 to 2.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for orthostatic hypotension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings caffeine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Caffeine compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Northern America</b> </p> <p><b>Intervention: caffeine</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>caffeine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.29 standard deviations lower (‐0.79 to 0.22). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours caffeine.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective fatigue severity in the intervention group was 0.19 standard deviations lower (‐0.32 to 0.69). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000 (2 to 509)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.03</p> <p>(0.07 to 15.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caffeine does increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>67 per 1000 (6 to 697)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.07</p> <p>(0.20 to 21.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caffeine does increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean HRQOL in the intervention group was 0.06 standard deviations higher (‐0.56 to 0.44).<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Negative SMD (‐0.06) in results section indicates better HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings methylphenidate</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methylphenidate compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Northern America</b> </p> <p><b>Intervention: methylphenidate</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>methylphenidate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.64 standard deviations lower (‐1.33 to 0.05). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate effect favours methylphenidate.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of physical fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of physical fatigue in the intervention group was 0.48 standard deviations lower (‐1.17 to 0.20). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours methylphenidate.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of mental fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of mental fatigue in the intervention group was 0.02 standard deviations higher (‐0.65 to 0.70). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>118 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>28 per 1000 (1 to 544)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.24</p> <p>(0.01 to 4.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does not increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>140 per 1000 (0 to 350)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.00</p> <p>(0.31 to 115.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>71 per 1000</p> <p>(5 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.21</p> <p>(0.08 to 17.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>24 per 1000 (1 to 536)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.40</p> <p>(0.02 to 9.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does not increase risk for tachycardia.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings modafinil</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Modafinil compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Europe and Northern America</b> </p> <p><b>Intervention: modafinil</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>modafinil</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.17 standard deviations lower (‐0.72 to 0.37). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of physical fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of physical fatigue in the intervention group was 1.23 standard deviations lower (‐2.36 to ‐0.11). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large effect favours modafinil.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of mental fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of mental fatigue in the intervention group was 0.05 standard deviations higher (‐0.97 to 1.06). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective fatigue severity in the intervention group was 0.08 standard deviations lower (‐0.73 to 0.56). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000 (0 to 190)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.14</p> <p>(0.35 to 27.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>286 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>166 per 1000</p> <p>(20 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.58</p> <p>(0.07 to 4.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does not increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>170 per 1000 (0 to 510)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.43</p> <p>(0.16 to 71.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000</p> <p>Moderate</p> <p>71 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000 (4 to 357)</p> <p>72 per 1000 (8 to 634)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01</p> <p>(0.11 to 8.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level because <a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a> scored ‘unclear risk’ for selection bias and ‘high risk’ for attrition bias. </p> <p><sup>b</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>c</sup>We downgraded the quality of the evidence by two levels because the estimate of effect is likely biased by imbalance at baseline. </p> <p><sup>d</sup>Absolute effect derived from risk difference (RD). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings doxepin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxepin compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Northern America</b> </p> <p><b>Intervention: doxepin</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>doxepin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean in subjective impact of fatigue in the intervention group was 1.50 standard deviations lower (‐2.84 to ‐0.15). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large effect favours doxepin.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>170 per 1000 (0 to 530)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00</p> <p>(0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxepin does increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>170 per 1000 (0 to 530)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00</p> <p>(0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxepin does increase risk for orthostatic hypotension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The change in mean HRQOL in the intervention group was 0.35 standard deviations higher (‐1.49 to 0.79).<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours doxepin.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of the evidence by two levels because <a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a> scored ‘high risk’ for selection bias, ‘high risk’ for performance bias and ‘high risk’ for detection bias. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> <p><sup>c</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>d</sup>Negative SMD (‐0.35) in results section indicates better HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010925-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings exercise</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Exercise compared with usual care for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: community, Australia, Europe</b> </p> <p><b>Intervention: exercise</b> </p> <p><b>Comparison: usual care</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>usual care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>exercise</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.45 standard deviations lower (‐1.21 to 0.32). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours exercise.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean HRQOL in the intervention group was 0.08 standard deviations higher (‐0.60 to 0.45).<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of the evidence by one level because blinding for assessment of fatigue (patient‐reported) not possible. </p> <p><sup>b</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>c</sup>Negative SMD (‐0.08) in results section indicates better HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010925-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010925-sec-0030"></div> <p>Fatigue is common in people with idiopathic Parkinson's disease (PD) and has a negative impact on health‐related quality of life (HRQOL) (<a href="./references#CD010925-bbs2-0096" title="HavlikovaE , RosenbergerJ , NagyoveI , MiddelB , DubayovaT , GdovinovaZ , et al. Impact of fatigue on quality of life in patients with Parkinson's disease. European Journal of Neurology2008;15:475‐80. ">Havlikova 2008</a>; <a href="./references#CD010925-bbs2-0098" title="HerlofsonK , LarsenJ . The influence of fatigue on health‐related quality of life in patients with Parkinson's disease. Acta Neurologica Scandinavica2003;107:1‐6. ">Herlofson 2003</a>; <a href="./references#CD010925-bbs2-0105" title="Martínez‐MartínP , CatalanM , Benito‐León , Ortega MorenoA , ZamarbideI , CuboE , et al. Impact of fatigue in Parkinson's disease: the fatigue impact scale for daily use (D‐FIS). Quality of Life Research2006;15:597‐606. ">Martínez‐Martín 2006</a>). Prevalence rates reported in the literature range from 32% to 50% (<a href="./references#CD010925-bbs2-0082" title="AlvesG , Wentzel‐LarsenT , LarsenJ . Is fatigue an independent and persistent symptom in patients with Parkinson's disease?. Neurology2004;63:1908‐11. ">Alves 2004</a>; <a href="./references#CD010925-bbs2-0097" title="HerlofsonK , LarsenJ . Measuring fatigue in patients with Parkinson's disease—the fatigue severity scale. European Journal of Neurology2002;9:595‐600. ">Herlofson 2002</a>). Fatigue usually refers to difficulty initiating or sustaining voluntary activity (<a href="./references#CD010925-bbs2-0084" title="ChaudhuriA , BehanP . Fatigue in neurological disorders. Lancet2004;363:978‐88. ">Chaudhuri 2004</a>). Its many facets are believed to result from a complex interplay between the underlying disease process, peripheral control systems (i.e. muscle fatigability), central control systems (i.e. subjective sense of fatigue) and environmental factors (<a href="./references#CD010925-bbs2-0084" title="ChaudhuriA , BehanP . Fatigue in neurological disorders. Lancet2004;363:978‐88. ">Chaudhuri 2004</a>). Subjective fatigue is often subdivided into physical and mental fatigue. Physical fatigue involves a sense of physical exhaustion and lack of energy to perform physical tasks despite the capacity and motivation to perform the task (<a href="./references#CD010925-bbs2-0092" title="FriedmanJ , AlvesG , HagellP , MarinusJ , MarshL , Martínez‐MartínP , et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society Task Force on rating scales for Parkinson's disease. Movement Disorders2010;25:805‐22. ">Friedman 2010</a>). Mental fatigue refers to the cognitive effects experienced during and after prolonged periods of cognitive activities that require sustained concentration and mental endurance (<a href="./references#CD010925-bbs2-0092" title="FriedmanJ , AlvesG , HagellP , MarinusJ , MarshL , Martínez‐MartínP , et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society Task Force on rating scales for Parkinson's disease. Movement Disorders2010;25:805‐22. ">Friedman 2010</a>). </p> <p>Although several potential pathophysiological mechanisms for fatigue, such as reduced concentrations of cytokines, inflammation, abnormalities of the hypothalamic adrenal axis and disturbances in the basal ganglia circuits, have been suggested (<a href="./references#CD010925-bbs2-0084" title="ChaudhuriA , BehanP . Fatigue in neurological disorders. Lancet2004;363:978‐88. ">Chaudhuri 2004</a>), the exact factors contributing to fatigue in people with PD are still not well known (<a href="./references#CD010925-bbs2-0091" title="FriedmanJ , BrownR , ComellaC , GarberC , KruppL , LouJ , et al. Fatigue in Parkinson's disease: a review. Movement Disorders2007;22:297‐308. ">Friedman 2007</a>). It is unlikely that a single mechanism contributes to subjective fatigue (<a href="./references#CD010925-bbs2-0093" title="FriedmanJ , AbrantesA , SweetL . Fatigue in Parkinson's disease. Expert Opinion on Pharmacotherapy2011;12:1999‐2007. ">Friedman 2011</a>), making it difficult to manage fatigue effectively in people with PD. </p> <p>Efforts to manage fatigue involve pharmacological and non‐pharmacological interventions. A balanced medication regime targeting motor performance (e.g. dopaminergic agents) and mood disturbances (e.g. psychostimulants and antidepressants) combined with a rehabilitation programme (e.g. exercise and cognitive‐behavioural therapy) may reduce symptoms of fatigue. An 'evidence‐based medicine review' about treatments for non‐motor symptoms of PD (<a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>) included three studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) that investigated the effect of methylphenidate or modafinil on fatigue. Seppi and colleagues concluded that evidence for the efficacy and safety of methylphenidate and modafinil in the treatment of fatigue in PD was insufficient (<a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>). In a recently published systematic review, Franssen and colleagues (<a href="./references#CD010925-bbs2-0090" title="FranssenM , WinwardC , ColletJ , WadeD , DawesH . Interventions for fatigue in Parkinson's disease: a systematic review and meta‐analysis. Movement Disorders2014;29:1675‐8. ">Franssen 2014</a>) investigated the effects of pharmacological and non‐pharmacological interventions on fatigue in people with PD. They concluded that insufficient evidence exists to support pharmacological or non‐pharmacological treatment of fatigue in people with PD (<a href="./references#CD010925-bbs2-0090" title="FranssenM , WinwardC , ColletJ , WadeD , DawesH . Interventions for fatigue in Parkinson's disease: a systematic review and meta‐analysis. Movement Disorders2014;29:1675‐8. ">Franssen 2014</a>). Unfortunately, this systematic review included only study reports published in English or Dutch. </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010925-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010925-sec-0031"></div> <p>To evaluate the effects of pharmacological and non‐pharmacological interventions, compared to an inactive control intervention, on subjective fatigue in people with PD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010925-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010925-sec-0032"></div> <section id="CD010925-sec-0033"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010925-sec-0034"> <h4 class="title">Types of studies</h4> <p>All types of randomised controlled trials (RCTs) that report on subjective fatigue as an outcome measure were eligible for inclusion. We did not restrict on the basis of publication language. </p> </section> <section id="CD010925-sec-0035"> <h4 class="title">Types of participants</h4> <p>People with a clinical diagnosis of PD, as defined by the authors of the RCT.</p> </section> <section id="CD010925-sec-0036"> <h4 class="title">Types of interventions</h4> <section id="CD010925-sec-0037"> <h5 class="title">Pharmacological interventions</h5> <p>We included dopaminergic agents (e.g. amantadine, levodopa), psychostimulants (e.g. methylphenidate, modafinil) and antidepressants (e.g. fluoxetine, paroxetine). If further agents were identified for the treatment of fatigue in people with PD, these were added to the systematic review. </p> </section> <section id="CD010925-sec-0038"> <h5 class="title">Non‐pharmacological interventions</h5> <section id="CD010925-sec-0039"> <h6 class="title">Exercise</h6> <p>All physical exercise programmes that focused on improvement in exercise capacity and consisted of aerobic training or strength training, or both. </p> </section> <section id="CD010925-sec-0040"> <h6 class="title">Cognitive‐behavioural therapy</h6> <p>All programs that focused on the behavioural or the cognitive aspects to substitute for or alter maladaptive behaviour to manage subjective fatigue. </p> </section> <section id="CD010925-sec-0041"> <h6 class="title">Other non‐pharmacological interventions</h6> <p>If other non‐pharmacological interventions were identified for the treatment of fatigue in people with PD, these were added to the systematic review. </p> </section> </section> <section id="CD010925-sec-0042"> <h5 class="title">Control intervention</h5> <p>All experimental interventions had to be compared with an inactive control intervention (i.e. placebo, no treatment, standard care, or a waiting list control). </p> </section> </section> <section id="CD010925-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD010925-sec-0044"> <h5 class="title">Primary outcomes</h5> <p>The primary outcomes for this systematic review were subjective fatigue, subjective physical fatigue and subjective mental fatigue as measured by self‐report questionnaires. If possible, we categorised the theoretical construct of fatigue as 'impact of fatigue on activities in daily life (ADL)' or 'fatigue severity' (<a href="./references#CD010925-bbs2-0087" title="ElbersR , RietbergM , VanWegenE , VerhoefJ , KramerS , TerweeC , et al. Self‐report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Quality of Life Research2012;21:925‐44. ">Elbers 2012a</a>). </p> <p>We examined the numbers of adverse effects (i.e. anxiety, falls, headache, hypertension, impulse control disorders, life‐threatening skin conditions, nausea, orthostatic hypotension, psychosis, suicidal ideation and tachycardia). </p> </section> <section id="CD010925-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes include depression, disease‐specific health‐related quality of life (HRQOL) and sleep disturbances. </p> <section id="CD010925-sec-0046"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p>The following outcomes were selected for the 'Summary of findings' table:</p> <p> <ul id="CD010925-list-0001"> <li> <p>subjective fatigue, subjective physical fatigue and subjective mental fatigue;</p> </li> <li> <p>anxiety, falls, headache, hypertension, impulse control disorders, life‐threatening skin conditions, nausea, orthostatic hypotension, psychosis, suicidal ideation and tachycardia; and </p> </li> <li> <p>HRQOL.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD010925-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010925-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 4) (<i>The Cochrane Library</i>) and additional searches of MEDLINE (via PubMed), Ovid EMBASE, EBSCO CINAHL, Ovid PsycINFO, PEDro (search.pedro.org.au/search) and the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal (http://apps.who.int/trialsearch) prospective trial register. Text words and MeSH terms for PD and fatigue were combined with the Cochrane Highly Sensitive Search Strategy to identify randomised trials (<a href="./references#CD010925-bbs2-0103" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We searched all databases from their inception to April 2015 (see Appendix 1). There were no restrictions based on language, date of publication or study setting. </p> </section> <section id="CD010925-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We screened references of included studies and identified review articles to look for additional studies. </p> </section> </section> <section id="CD010925-sec-0050"> <h3 class="title" id="CD010925-sec-0050">Data collection and analysis</h3> <section id="CD010925-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RE/JV) independently screened titles and abstracts of all studies identified by the search strategy. Irrelevant studies were discarded. For the remaining studies, full text papers were obtained and two review authors (RE/JV) independently applied the a priori defined selection criteria. We resolved any disagreement by discussion. If necessary, we consulted a third review author (EvW) to make a final decision. </p> </section> <section id="CD010925-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>A form for standardised data extraction was designed and tested before two review authors (RE/JV) independently extracted data on the: </p> <p> <ul id="CD010925-list-0002"> <li> <p>characteristics of the study sample (i.e. inclusion/exclusion criteria, number of people randomly assigned, age, sex, disease severity, disease duration and comorbid conditions); </p> </li> <li> <p>experimental and control intervention (i.e. description of intervention, dosage, frequency and duration of delivery); </p> </li> <li> <p>outcome measures (i.e. description of outcome measure); and</p> </li> <li> <p>results (i.e. number of people, point estimates, measures of variance and frequency counts for dichotomous variables). </p> </li> </ul> </p> <p>One review author (RE) collated and entered all data into Review Manager 5.3 (Review Manager version 5.3, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). We resolved any disagreement by discussion. </p> </section> <section id="CD010925-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RE/JV) independently used The Cochrane Collaboration tool for assessing risk of bias (<a href="./references#CD010925-bbs2-0101" title="HigginsJ , AltmanD , SterneJ (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. Available from www.cochrane‐handbook.org.. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) to investigate the risk of bias in included studies. We scored seven domains of study design (i.e. sequence generation, allocation concealment, blinding of participants or personnel, blinding of outcome assessors, incomplete outcome data, selective reporting and other bias) according to predefined criteria (<a href="./references#CD010925-bbs2-0101" title="HigginsJ , AltmanD , SterneJ (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. Available from www.cochrane‐handbook.org.. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) as 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'. We investigated the domain blinding separately for different outcomes, and examined the domain incomplete outcome data separately for the same outcome at different time points. We resolved any disagreement by discussion. If necessary, RE and JV consulted a third review author (EvW) to make a final decision. </p> </section> <section id="CD010925-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010925-sec-0055"> <h5 class="title">Continuous data</h5> <p>The treatment effect for each continuous outcome was expressed as a standardised mean difference (SMD) with 95% confidence interval (CI). We used post‐intervention data to calculate the SMD (<a href="./references#CD010925-bbs2-0086" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD010925-sec-0056"> <h5 class="title">Dichotomous data</h5> <p>The treatment effect for each dichotomous outcome was expressed as a risk ratio (RR) or as a risk difference (RD) with 95% CI. </p> </section> </section> <section id="CD010925-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <section id="CD010925-sec-0058"> <h5 class="title">Studies with multiple treatment groups</h5> <p>We combined data from relevant experimental intervention groups and relevant control intervention groups to create a single pair‐wise comparison (<a href="./references#CD010925-bbs2-0086" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> </section> <section id="CD010925-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>If necessary, we used additional publications to obtain missing data. No statistical methods were used to impute missing data. </p> </section> <section id="CD010925-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was investigated by comparing clinical characteristics such as patient characteristics, types of interventions and outcome measures. We discussed clinical homogeneity, and based on this discussion, we decided whether pooling of data was sensible. We assessed statistical heterogeneity by visual inspection of the forest plot. We applied the Chi<sup>2</sup> test for homogeneity and calculated the I<sup>2</sup> statistic (<a href="./references#CD010925-bbs2-0100" title="HigginsJ , ThompsonS , DeeksJ , AltmanD . Measuring inconsistency in meta‐analyses. BMJ2003; Vol. 327:557‐60. ">Higgins 2003</a>). To increase the power of the test for homogeneity we used a P value &lt; 0.1 for rejecting the null‐hypothesis of homogeneity. Thresholds for the interpretation of the I<sup>2</sup> statistic were classified according the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010925-bbs2-0086" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> <p>When interpreting the results of the test for homogeneity and the I<sup>2</sup> statistic, we took into account the size of the studies that were included in the meta‐analysis. If statistical heterogeneity was observed (Chi<sup>2</sup> test P value &lt; 0.1 and I<sup>2</sup> statistic &gt; 30%) we explored factors that explained heterogeneity. </p> </section> <section id="CD010925-sec-0061"> <h4 class="title">Data synthesis</h4> <p>If studies were comparable in relation to participants, interventions and outcomes, data were combined in a meta‐analysis. For continuous outcome variables a weighted SMD was calculated with a 95% CI, using the inverse variance method. For dichotomous outcomes we estimated a pooled RR or RD with a 95% CI using the Mantel‐Haenszel method. When incorporating results from cluster‐randomised trials or studies that presented direct estimates of effect, we used the generic inverse variance method. </p> <p>We hypothesised that the individual studies that evaluated the effects of pharmacological or non‐pharmacological interventions may contain different, but related, real effects per study; therefore we combined results using a random‐effects model. </p> </section> <section id="CD010925-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses:</p> <p> <ul id="CD010925-list-0003"> <li> <p>depressed versus non‐depressed people; and</p> </li> <li> <p>people with pronounced physical fatigue versus people with pronounced mental fatigue.</p> </li> </ul> </p> </section> <section id="CD010925-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <section id="CD010925-sec-0064"> <h5 class="title">Random‐effects model</h5> <p>If a limited number of studies (&lt; five) was included in any meta‐analysis, we used a fixed‐effect model to test the robustness of the random‐effects model. </p> </section> <section id="CD010925-sec-0065"> <h5 class="title">Risk of bias</h5> <p>To test the robustness of results, we used three key domains of the risk of bias assessment (i.e. allocation concealment, blinding of outcome assessment and incomplete outcome data) to perform a sensitivity analysis. We excluded studies from the sensitivity analysis when they scored 'unclear risk of bias' or 'high risk of bias' on one of these domains. </p> <p>If blinding of participants was not possible because of the nature of the intervention, we did not consider detection bias for participant‐reported outcomes as a criterion for sensitivity analysis. </p> </section> <section id="CD010925-sec-0066"> <h5 class="title">Quality of the evidence</h5> <p>We evaluated the quality of the body of evidence using the GRADE system (<a href="./references#CD010925-bbs2-0106" title="SchünemannH , OxmanA , VistG , HigginsJ , DeeksJ , GlasziouP , GuyattG . Chapter 12: Interpreting results and drawing conclusions. In: Higgins J, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Schünemann 2011</a>). We considered the results of a RCT as 'high quality’ evidence. The quality of the evidence was decreased based on potential risk of bias of the included studies, indirectness of evidence, unexplained heterogeneity or inconsistency in results, imprecision of results or high probability of publication bias (<a href="./references#CD010925-bbs2-0106" title="SchünemannH , OxmanA , VistG , HigginsJ , DeeksJ , GlasziouP , GuyattG . Chapter 12: Interpreting results and drawing conclusions. In: Higgins J, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Schünemann 2011</a>). </p> <p>We facilitated the interpretation of the magnitude of effects by using criteria proposed by Cohen (<a href="./references#CD010925-bbs2-0085" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988. ">Cohen 1988</a>); a weighted SMD of 0.2 represents a small difference, 0.5 a moderate difference and 0.8 a large difference. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010925-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010925-sec-0067"></div> <section id="CD010925-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD010925-sec-0069"> <h4 class="title">Results of the search</h4> <p>The search yielded 1,300 records, of which 78 studies were retrieved in full text for further assessment. This resulted in the exclusion of another 65 studies (<a href="./references#CD010925-bbs2-0012" title="AbeK , TakanashiM , YanagiharaT , SakodaS . Pergolide mesilate may improve fatigue in patients with Parkinson's disease. Behavioural Neurology2001;13:117‐21. ">Abe 2001</a>; <a href="./references#CD010925-bbs2-0013" title="BaroneP , PoeweW , AlbrechtS , DebieuvreC , MasseyD , RascolO , et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2010;9:573‐80. ">Barone 2010</a>; <a href="./references#CD010925-bbs2-0014" title="BaroneP . Treatment of depressive symptoms in Parkinson's disease. European Journal of Neurology2011;18:11‐5. ">Barone 2011</a>; <a href="./references#CD010925-bbs2-0015" title="BermanR , ThaseM , TrivediM , HazelJ , Vogel MarlerS , McQuadeR , et al. Long‐term safety and tolerability of open‐label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment2011;7:303‐12. ">Berman 2011</a>; <a href="./references#CD010925-bbs2-0016" title="BlindauerK , ShoulsonI , KieburtzK , McDermottM , GardinerI , KampC , et al. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Archives of Neurology2003;60:1721‐8. ">Blindauer 2003</a>; <a href="./references#CD010925-bbs2-0017" title="BorgohainR , SzaszJ , StanzioneP , MeshramC , BhattM , ChirillineauD , et al. Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease. Movement Disorders2014;29:1273‐80. ">Borgohain 2014</a>; <a href="./references#CD010925-bbs2-0018" title="BronzovaJ , SampaioC , HauserR , LangA , RascolO , TheeuwesA , et al. Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement Disorders2010;25:738‐46. ">Bronzova 2010</a>; <a href="./references#CD010925-bbs2-0019" title="BrooksD , SagarH . Entacapone is beneficial in both fluctuating and non‐fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology, Neurosurgery and Psychiatry2003;74:1071‐9. ">Brooks 2003</a>; <a href="./references#CD010925-bbs2-0020" title="ChaudhuriK , Martínez‐MartínP , AntoniniA , BrownR , FriedmanJ , OnofrjM , et al. Rotigotine and specific non‐motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism and Related Disorders2013;19:660‐5. ">Chaudhuri 2013</a>; <a href="./references#CD010925-bbs2-0021" title="ChwiedukC , CurranM . Pramipexole extended release in Parkinson's disease. CNS Drugs2010;24:327‐36. ">Chwieduk 2010</a>; <a href="./references#CD010925-bbs2-0022" title="ConradssonD , LofgrenN , HagstromerM , StahleA , FranzenE . A highly challenging, progressive and specific balance training program in elderly with Parkinson’s disease: theoretical framework and feasibility. European Journal of Neurology2013;19:S571. ">Conradsson 2013</a>; <a href="./references#CD010925-bbs2-0023" title="CugusiL , SollaP , ZeddaF , LoiM , SerpeR , CannasA , et al. Effects of an adapted physical activity program on motor and non‐motor functions and quality of life in patients with Parkinson's disease. Neurorehabilitation2014;35:789‐94. ">Cugusi 2014</a>; <a href="./references#CD010925-bbs2-0024" title="DashtipourK , JohnsonE , KaniC , KaniK , HadiE , GhamsaryM , et al. Effect of exercise in motor and nonmotor symptoms of Parkinson's disease. Parkinson's Disease2015;2015:586378. ">Dashtipour 2015</a>; <a href="./references#CD010925-bbs2-0025" title="DatievaV , RosinskaiaA , LevinO . The use of melatonin in the treatment of chronic fatigue sundrome and circadian rhythm disorders in Parkinson’s disease. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsokova2013;113:77‐81. ">Datieva 2013</a>; <a href="./references#CD010925-bbs2-0026" title="DeuschlG , VaitkusA , FoxG , RoscherT , SchremmerD , GordinA . Efficacy and tolerability of entacapone versus cabergoline in Parkinsonian patients suffering from wearing‐off. Movement Disorders2007;22:1550‐5. ">Deuschl 2007</a>; <a href="./references#CD010925-bbs2-0027" title="DevosD , KrystkowiakP , ClementF , DujardinK , CottencinO , WaucquierN , et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry2007;78:470‐5. ">Devos 2007</a>; <a href="./references#CD010925-bbs2-0028" title="DobatoJ , Pérez‐GilabertY , deAndrésC , Muñoz‐BlancoJ , MateoD , Giménez‐RoldánS . Effect of amantadine on fatigue in Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis [Efecto del amantadine en la fatiga de la enfermedad de Parkinson, la esclerósis múltiple y la esclerósis lateral amiotrófica]. NeurologÌa1994;9:460. ">Dobato 1994</a>; <a href="./references#CD010925-bbs2-0029" title="DowlingG , MastickJ , CollingE , CarterJ , SingerC , AminoffM . Melatonin for sleep disturbances in Parkinson's disease. Sleep Medicine2005;6:459‐66. ">Dowling 2005</a>; <a href="./references#CD010925-bbs2-0030" title="DrijgersR , VerheyF , TissinghG , vanDomburgP , AaltenP , LeentjensA . The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo controlled experimental challenge with pramipexole and methylphenidate. Journal of the Neurological Sciences2012;320:121‐6. ">Drijgers 2012</a>; <a href="./references#CD010925-bbs2-0031" title="FernandezH , GreeleyD , ZweigR , WojcieszekJ , MoriA , SussmanN . Istradefylline as monotherapy for Parkinson disease: results of the 6002‐US‐051 trial. Parkinsonism and Related Disorders2010;16:16‐20. ">Fernandez 2010</a>; <a href="./references#CD010925-bbs2-0032" title="GençA , Dönmez ÇolakoğluB , KaraB , ÇakmurR . Evaluation of the effects of home‐based deep breathing exercises in Parkinson's disease patients. Archives of Neuropsychiatry2012;49:59‐62. ">Genç 2012</a>; <a href="./references#CD010925-bbs2-0033" title="GhahariS , PackerT , PassmoreA . Effectiveness of an online fatigue self‐management programme for people with chronic neurological conditions: a randomized controlled trial. Clinical Rehabilitation2010;24:727‐44. ">Ghahari 2010</a>; <a href="./references#CD010925-bbs2-0034" title="GrossetK , GrossetD , LeesA . Trial of subtherapeutic pergolide in de novo Parkinson's disease. Movement Disorders2005;20:363‐6. ">Grosset 2005</a>; <a href="./references#CD010925-bbs2-0035" title="HauserR , SalinL , JuhelN , KonyagoV . Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement Disorders2007;22:359‐65. ">Hauser 2007</a>; <a href="./references#CD010925-bbs2-0036" title="HauserR , LyonsK , McClainT , CarterS , PerlmutterD . Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders2009;24:979‐83. ">Hauser 2009</a>; <a href="./references#CD010925-bbs2-0037" title="HauserR , SchapiraA , RascolO , BaroneP , MizunoY , SalinL , et al. Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders2010;25:2542‐9. ">Hauser 2010</a>; <a href="./references#CD010925-bbs2-0038" title="HeikkinenH , NuttJ , LeWittP , KollerW , GordinA . The effects of different repeated doses of entacapone on the pharmacokinetics of l‐dopa and on the clinical response to l‐dopa in Parkinson's disease. Clinical Neuropharmacology2001;24:150‐7. ">Heikkinen 2001</a>; <a href="./references#CD010925-bbs2-0039" title="JangW , ParkJ , ShinK , KimJ , KimJ , YounJ , et al. Safety and efficacy of recombinant human erythropoietin treatment of non‐motor symptoms in Parkinson's disease. Journal of the Neurological Sciences2014;337:47‐54. ">Jang 2014</a>; <a href="./references#CD010925-bbs2-0040" title="JankovicJ , WattsR , MartinW , BoroojerdiB . Transdermal rotigotine: double‐blind, placebo‐controlled trial in Parkinson disease. Archives of Neurology2007;64:676‐82. ">Jankovic 2007</a>; <a href="./references#CD010925-bbs2-0041" title="KieburtzK , McDermottM , ShoulsonI , FahnS , BrinM , GoetzC , et al. Effect of lazabemide on the progression of disability in early Parkinson's disease. Annals of Neurology1996;40:99‐107. ">Kieburtz 1996</a>; <a href="./references#CD010925-bbs2-0042" title="KieburtzK , The Parkinson Study Group PramiBID Investigators. Twice‐daily, low dose Pramipexole in early Parkinson's disease:a randomized, placebo‐controlled trial. Movement Disorders2011;26:37‐44. ">Kieburtz 2011</a>; <a href="./references#CD010925-bbs2-0043" title="LeentjensA , ScholtissenB , VreelingF , VerheyF . The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology2006;31:1009‐15. ">Leentjens 2006</a>; <a href="./references#CD010925-bbs2-0044" title="LeroiI , BrandtJ , ReichS , LyketsosC , GrillS , ThompsonR , et al. Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease. International Journal of Geriatric Psychiatry2004;19:1‐8. ">Leroi 2004</a>; <a href="./references#CD010925-bbs2-0045" title="LimT , KlugerB , RodriguezR , PalacioR , GuiratiY , NutterB , et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease: a 3‐center, placebo‐controlled, pilot study (the REST trial). Movement Disorders2013;28:S165. ">Lim 2013</a>; <a href="./references#CD010925-bbs2-0046" title="LouJ , KearnsG , BeniceT , OkenB , SextonG , NuttJ . Levodopa improves physical fatigue in Parkinson's diseae: a double‐blind, placebo‐controlled, crossover study. Movement Disorders2003;18:1108‐14. ">Lou 2003</a>; <a href="./references#CD010925-bbs2-0047" title="MeekC , SackleyC , ClarkeC , SoundyA , WinwardC , EsserP , et al. Long‐term individual fitness enablement (LIFE) for Parkinson's disease: a feasibility study. Movement Disorders2010;25:S713. ">Meek 2010</a>; <a href="./references#CD010925-bbs2-0048" title="MenzaM , DobkinR , MarinH , MarkM , GaraM , BuyskeS , et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology2009;72:886‐92. ">Menza 2009</a>; <a href="./references#CD010925-bbs2-0049" title="MöllerJ , OertelW , KösterJ , PezzoliG , ProvincialiL . Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Movement Disorders2005;20:602‐10. ">Möller 2005</a>; <a href="./references#CD010925-bbs2-0050" title="MoritaA , OkumaY , KameiS , YoshiiF , YamamotoT , HashimotoS , et al. Pramipexole reduces the prevalence of fatigue in patients with Parkinson's disease. Internal Medicine2011;50:2163‐8. ">Morita 2011</a>; <a href="./references#CD010925-bbs2-0051" title="NuttJ , CarterJ , CarlsonN . Effects of methylphenidate on response to oral levodopa. Archives of Neurology2007;64:319‐23. ">Nutt 2007</a>; <a href="./references#CD010925-bbs2-0052" title="OkunM , FernandezH , RodriguezR , RomrellJ , SuelterM , MunsonS , et al. Testosterone therapy in men with Parkinson disease. Archives of Neurology2006;63:729‐35. ">Okun 2006</a>; <a href="./references#CD010925-bbs2-0053" title="OlanowC , KieburtzK , SternM , WattsR , LangstonW , GuarnieriM , et al. Double‐blind, placebo‐controlled study of entacapone in levodopa‐treated patients with stable Parkinson disease. Archives of Neurology2004;61:1563‐8. ">Olanow 2004</a>; <a href="./references#CD010925-bbs2-0054" title="OndoW , PerkinsT , SwickT , HullK , JimenezJ , GarrisT , et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease. Archives of Neurology2008;65:1337‐40. ">Ondo 2008</a>; <a href="./references#CD010925-bbs2-0055" title="OvedD , ZivI , TrevesT , PaleacuD , MelamedE , DjaldettiR . Effect of dopamine agonist on fatigue and somnolence in Parkinson's disease. Movement Disorders2006;21:1257‐61. ">Oved 2006</a>; <a href="./references#CD010925-bbs2-0056" title="PinterM , PogarellO , OertelW . Efficacy, safety, and tolerance of the non‐ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. Journal of Neurology, Neurosurgery and Psychiatry1999;66:436‐41. ">Pinter 1999</a>; <a href="./references#CD010925-bbs2-0057" title="PogarellO , GasserT , vanHiltenJ , SpiekerS , PollentierS , MeierD , et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Journal of Neurology, Neurosurgery and Psychiatry2002;72:713‐20. ">Pogarell 2002</a>; <a href="./references#CD010925-bbs2-0058" title="PourcherE , FernandezH , StacyM , MoriA , BalleriniR , ChaikinP . Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW‐6002‐US‐018 study. Parkinsonism and Related Disorders2012;18:178‐84. ">Pourcher 2012</a>; <a href="./references#CD010925-bbs2-0059" title="RichardI , McDermottM , KurlanR , LynessJ , ComoP , PearsonN , et al. A randomized, double‐blind, placebo‐controlled trial of antidepressants in Parkinson disease. Neurology2012;78:1229‐36. ">Richard 2012</a>; <a href="./references#CD010925-bbs2-0060" title="Rios RomenetsS , AnangJ , FereshtehnejadS , PelletierA , PostumaR . Tango for treatment of motor and non‐motor manifestations in Parkinson's disease: a randomized control study. Complementary Therapies in Medicine2015;23:175‐84. ">Rios Romenets 2015</a>; <a href="./references#CD010925-bbs2-0061" title="SampaioC , BronzovaJ , HauserR , LangA , RascolO , Van deWitteS , et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double‐blind trials. Movement Disorders2011;26:1464‐76. ">Sampaio 2011</a>; <a href="./references#CD010925-bbs2-0062" title="SchapiraA , McDermottM , BaroneP , ComellaC , AlbrechtsS , HsuH , et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed‐start trial. The Lancet Neurology2013;12:747‐55. ">Schapira 2013</a>; <a href="./references#CD010925-bbs2-0063" title="SethiK , O'BrienC , HammerstadJ , AdlerC , DavisT , TaylorR , et al. Ropinirole for the treatment of early Parkinson disease: a 12‐month experience. Archives of Neurology1998;55:1211‐6. ">Sethi 1998</a>; <a href="./references#CD010925-bbs2-0064" title="ShoulsonI , OakesD , FahnS , LangA , LangstonW , LeWittP , et al. Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: a randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Annals of Neurology2002;51:604‐12. ">Shoulson 2002</a>; <a href="./references#CD010925-bbs2-0065" title="SingerC , LambJ , EllisA , LaytonG . A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Movement Disorders2007;22:476‐82. ">Singer 2007</a>; <a href="./references#CD010925-bbs2-0066" title="StocchiF . Benefits of treatment with rasagiline in fatigue symptoms in patients with early Parkinson's disease. European Journal of Neurology2009;16:S525. ">Stocchi 2009</a>; <a href="./references#CD010925-bbs2-0067" title="StocchiF . Treatment with rasagiline provides benefits in the symptoms of fatigue in patients with early Parkinson's disease. Movement Disorders2010;25:S676. ">Stocchi 2010</a>; <a href="./references#CD010925-bbs2-0068" title="StocchiF , RascolO , DesteeA , HattoriN , HauserR , LangA , et al. AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study. Movement Disorders2013;28:1838‐46. ">Stocchi 2013</a>; <a href="./references#CD010925-bbs2-0069" title="StocchiF , The ADAGIO Investigators. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. European Journal of Neurology2014;21:357‐60. ">Stocchi 2014</a>; <a href="./references#CD010925-bbs2-0070" title="SturkenboomI , GraffM , HendriksJ , VeenhuizenY , MunnekeM , BloemB , et al. Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. The Lancet Neurology2014;13:557‐66. ">Sturkenboom 2014</a>; <a href="./references#CD010925-bbs2-0071" title="TodorovaA , Martinez‐MartinP , MartinA , RizosA , ReddyP , ChaudhuriK . Datyime apomorphine infusion combined with transdermal rotigotine patch therapy is tolerated at 2 years: a 24‐h treatment option in Parkinson's disease. Basal Ganglia2013;3:127‐30. ">Todorova 2013</a>; <a href="./references#CD010925-bbs2-0072" title="TrenkwalderC , ZucconiM , TolosaE , SurmannE , WhitesidesJ , BoroojerdiB , et al. Effect of rotigotine on sleep outcomes in Parkinson's disease: recover study. Journal of Sleep Research2010;19:S23‐S4. ">Trenkwalder 2010</a>; <a href="./references#CD010925-bbs2-0073" title="UcE , DoerschugK , MagnottaV , DawsonJ , ThomsenT , KlineJ , et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology2014;83:413‐25. ">Uc 2014</a>; <a href="./references#CD010925-bbs2-0074" title="WattsR , JankovicJ , WatersC , RajputA , BoroojerdiB , RaoJ . Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology2007;68:272‐7. ">Watts 2007</a>; <a href="./references#CD010925-bbs2-0075" title="ZhangL , ZhangZ , ChenY , QinX , ZhouH , ZhangC , et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson’s disease: a randomized, double‐blind, parallel‐controlled, multi‐centre trial. International Journal of Neuropsychopharmacology2013;16:1529‐37. ">Zhang 2013a</a>; <a href="./references#CD010925-bbs2-0076" title="ZhangZ , WangJ , ZhangX , ChenS , WangZ , ZhangB , et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double‐blind, randomized, placebo‐controlled study. Parkinsonism and Related Disorders2013;19:1022‐6. ">Zhang 2013b</a>). Two studies are awaiting classification (<a href="./references#CD010925-bbs2-0077" title="PahwaR , TannerC , HauserR , SethiK , IsaacsonS , TruongD , et al. Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED study). Movement Disorders2015;30:788‐95. ">Pahwa 2015</a>; <a href="./references#CD010925-bbs2-0078" title="SmithK , EyalE , WeintraubD . Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study. JAMA Neurology2015;72:88‐95. ">Smith 2015</a>) and 11 studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>; <a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>; <a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>; <a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) were included in the systematic review (see <a href="#CD010925-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010925-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010925-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010925-sec-0070"> <h4 class="title">Included studies</h4> <p>Details about the included studies are summarised in the <a href="./references#CD010925-sec-0104" title="">Characteristics of included studies</a> table. Three studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) included only people who experienced clinically relevant fatigue (Fatigue Severity Scale (FSS) score ≥ 4 out of 7 (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) or Multidimensional Fatigue Inventory total score (MFI‐total) &gt; 48 out of 100 (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>), whereas eight studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>; <a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>; <a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>; <a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) did not select participants on the basis of experienced fatigue. Four studies (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) excluded people with depressive symptoms. </p> <p>The effects of pharmacological interventions were investigated in nine studies. Three studies investigated the effect of dopaminergic medication (i.e. levodopa‐carbidopa (<a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>), memantine (<a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>) and rasagiline (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>)), and five studies investigated the effect of psychostimulants (i.e. caffeine (<a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>), methylphenidate (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>) and modafinil (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>)) on subjective fatigue. One study (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>) investigated the effects of antidepressants (i.e. doxepin). All studies were placebo‐controlled. </p> <p>Non‐pharmacological interventions were investigated in two studies. One study (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>) investigated the effect of home‐based treadmill training, semi‐supervised by a physiotherapist. The other study (<a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) investigated the effect of a supervised community gym‐based programme. Participants were supported with information and practical advice from a physiotherapist. Both studies compared the experimental intervention with usual care. </p> <p>Overall, a total of 1817 people were included in the systematic review. Mean age ranged from 57 years (<a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) to 70 years (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>) and mean disease severity, classified by Hoehn and Yahr stage (H&amp;Y), ranged from 1.5 (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>) to 2.6 (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>). The mean disease duration ranged from 4.0 years (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) to 8.0 years (<a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>); two studies (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>) included people with recently diagnosed PD (mean disease duration ranged from 4.3 months (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>) to 7.6 months (<a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>). </p> <p>Different self‐report questionnaires were used to measure subjective fatigue. Most studies (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>; <a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>; <a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) used the FSS to assess the impact of fatigue on ADL and fatigue severity. Two studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>) used the MFI to assess the impact of physical and mental fatigue on ADL, and one study (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>) used the Parkinson Fatigue Scale (PFS‐16) to measure the impact of physical fatigue on ADL. In most studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>; <a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>; <a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>; <a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>), mean baseline levels of fatigue approached cut‐off points for clinically relevant fatigue. Baseline levels of fatigue in the three studies that specifically included people with clinically relevant fatigue (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) were considerably higher. </p> </section> <section id="CD010925-sec-0071"> <h4 class="title">Excluded studies</h4> <p>Thirty‐two studies (<a href="./references#CD010925-bbs2-0013" title="BaroneP , PoeweW , AlbrechtS , DebieuvreC , MasseyD , RascolO , et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2010;9:573‐80. ">Barone 2010</a>; <a href="./references#CD010925-bbs2-0016" title="BlindauerK , ShoulsonI , KieburtzK , McDermottM , GardinerI , KampC , et al. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Archives of Neurology2003;60:1721‐8. ">Blindauer 2003</a>; <a href="./references#CD010925-bbs2-0017" title="BorgohainR , SzaszJ , StanzioneP , MeshramC , BhattM , ChirillineauD , et al. Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease. Movement Disorders2014;29:1273‐80. ">Borgohain 2014</a>; <a href="./references#CD010925-bbs2-0018" title="BronzovaJ , SampaioC , HauserR , LangA , RascolO , TheeuwesA , et al. Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement Disorders2010;25:738‐46. ">Bronzova 2010</a>; <a href="./references#CD010925-bbs2-0019" title="BrooksD , SagarH . Entacapone is beneficial in both fluctuating and non‐fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology, Neurosurgery and Psychiatry2003;74:1071‐9. ">Brooks 2003</a>; <a href="./references#CD010925-bbs2-0026" title="DeuschlG , VaitkusA , FoxG , RoscherT , SchremmerD , GordinA . Efficacy and tolerability of entacapone versus cabergoline in Parkinsonian patients suffering from wearing‐off. Movement Disorders2007;22:1550‐5. ">Deuschl 2007</a>; <a href="./references#CD010925-bbs2-0031" title="FernandezH , GreeleyD , ZweigR , WojcieszekJ , MoriA , SussmanN . Istradefylline as monotherapy for Parkinson disease: results of the 6002‐US‐051 trial. Parkinsonism and Related Disorders2010;16:16‐20. ">Fernandez 2010</a>; <a href="./references#CD010925-bbs2-0034" title="GrossetK , GrossetD , LeesA . Trial of subtherapeutic pergolide in de novo Parkinson's disease. Movement Disorders2005;20:363‐6. ">Grosset 2005</a>; <a href="./references#CD010925-bbs2-0035" title="HauserR , SalinL , JuhelN , KonyagoV . Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement Disorders2007;22:359‐65. ">Hauser 2007</a>; <a href="./references#CD010925-bbs2-0036" title="HauserR , LyonsK , McClainT , CarterS , PerlmutterD . Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders2009;24:979‐83. ">Hauser 2009</a>; <a href="./references#CD010925-bbs2-0037" title="HauserR , SchapiraA , RascolO , BaroneP , MizunoY , SalinL , et al. Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders2010;25:2542‐9. ">Hauser 2010</a>; <a href="./references#CD010925-bbs2-0038" title="HeikkinenH , NuttJ , LeWittP , KollerW , GordinA . The effects of different repeated doses of entacapone on the pharmacokinetics of l‐dopa and on the clinical response to l‐dopa in Parkinson's disease. Clinical Neuropharmacology2001;24:150‐7. ">Heikkinen 2001</a>; <a href="./references#CD010925-bbs2-0040" title="JankovicJ , WattsR , MartinW , BoroojerdiB . Transdermal rotigotine: double‐blind, placebo‐controlled trial in Parkinson disease. Archives of Neurology2007;64:676‐82. ">Jankovic 2007</a>; <a href="./references#CD010925-bbs2-0041" title="KieburtzK , McDermottM , ShoulsonI , FahnS , BrinM , GoetzC , et al. Effect of lazabemide on the progression of disability in early Parkinson's disease. Annals of Neurology1996;40:99‐107. ">Kieburtz 1996</a>; <a href="./references#CD010925-bbs2-0042" title="KieburtzK , The Parkinson Study Group PramiBID Investigators. Twice‐daily, low dose Pramipexole in early Parkinson's disease:a randomized, placebo‐controlled trial. Movement Disorders2011;26:37‐44. ">Kieburtz 2011</a>; <a href="./references#CD010925-bbs2-0044" title="LeroiI , BrandtJ , ReichS , LyketsosC , GrillS , ThompsonR , et al. Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease. International Journal of Geriatric Psychiatry2004;19:1‐8. ">Leroi 2004</a>; <a href="./references#CD010925-bbs2-0048" title="MenzaM , DobkinR , MarinH , MarkM , GaraM , BuyskeS , et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology2009;72:886‐92. ">Menza 2009</a>; <a href="./references#CD010925-bbs2-0049" title="MöllerJ , OertelW , KösterJ , PezzoliG , ProvincialiL . Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Movement Disorders2005;20:602‐10. ">Möller 2005</a>; <a href="./references#CD010925-bbs2-0053" title="OlanowC , KieburtzK , SternM , WattsR , LangstonW , GuarnieriM , et al. Double‐blind, placebo‐controlled study of entacapone in levodopa‐treated patients with stable Parkinson disease. Archives of Neurology2004;61:1563‐8. ">Olanow 2004</a>; <a href="./references#CD010925-bbs2-0056" title="PinterM , PogarellO , OertelW . Efficacy, safety, and tolerance of the non‐ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. Journal of Neurology, Neurosurgery and Psychiatry1999;66:436‐41. ">Pinter 1999</a>; <a href="./references#CD010925-bbs2-0057" title="PogarellO , GasserT , vanHiltenJ , SpiekerS , PollentierS , MeierD , et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Journal of Neurology, Neurosurgery and Psychiatry2002;72:713‐20. ">Pogarell 2002</a>; <a href="./references#CD010925-bbs2-0058" title="PourcherE , FernandezH , StacyM , MoriA , BalleriniR , ChaikinP . Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW‐6002‐US‐018 study. Parkinsonism and Related Disorders2012;18:178‐84. ">Pourcher 2012</a>; <a href="./references#CD010925-bbs2-0059" title="RichardI , McDermottM , KurlanR , LynessJ , ComoP , PearsonN , et al. A randomized, double‐blind, placebo‐controlled trial of antidepressants in Parkinson disease. Neurology2012;78:1229‐36. ">Richard 2012</a>; <a href="./references#CD010925-bbs2-0061" title="SampaioC , BronzovaJ , HauserR , LangA , RascolO , Van deWitteS , et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double‐blind trials. Movement Disorders2011;26:1464‐76. ">Sampaio 2011</a>; <a href="./references#CD010925-bbs2-0062" title="SchapiraA , McDermottM , BaroneP , ComellaC , AlbrechtsS , HsuH , et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed‐start trial. The Lancet Neurology2013;12:747‐55. ">Schapira 2013</a>; <a href="./references#CD010925-bbs2-0063" title="SethiK , O'BrienC , HammerstadJ , AdlerC , DavisT , TaylorR , et al. Ropinirole for the treatment of early Parkinson disease: a 12‐month experience. Archives of Neurology1998;55:1211‐6. ">Sethi 1998</a>; <a href="./references#CD010925-bbs2-0064" title="ShoulsonI , OakesD , FahnS , LangA , LangstonW , LeWittP , et al. Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: a randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Annals of Neurology2002;51:604‐12. ">Shoulson 2002</a>; <a href="./references#CD010925-bbs2-0065" title="SingerC , LambJ , EllisA , LaytonG . A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Movement Disorders2007;22:476‐82. ">Singer 2007</a>; <a href="./references#CD010925-bbs2-0068" title="StocchiF , RascolO , DesteeA , HattoriN , HauserR , LangA , et al. AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study. Movement Disorders2013;28:1838‐46. ">Stocchi 2013</a>; <a href="./references#CD010925-bbs2-0074" title="WattsR , JankovicJ , WatersC , RajputA , BoroojerdiB , RaoJ . Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology2007;68:272‐7. ">Watts 2007</a>; <a href="./references#CD010925-bbs2-0075" title="ZhangL , ZhangZ , ChenY , QinX , ZhouH , ZhangC , et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson’s disease: a randomized, double‐blind, parallel‐controlled, multi‐centre trial. International Journal of Neuropsychopharmacology2013;16:1529‐37. ">Zhang 2013a</a>; <a href="./references#CD010925-bbs2-0076" title="ZhangZ , WangJ , ZhangX , ChenS , WangZ , ZhangB , et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double‐blind, randomized, placebo‐controlled study. Parkinsonism and Related Disorders2013;19:1022‐6. ">Zhang 2013b</a>) were excluded because fatigue was measured as an adverse effect related to study medication and no details were provided on whether self‐report questionnaires were used for assessment. Two studies (<a href="./references#CD010925-bbs2-0020" title="ChaudhuriK , Martínez‐MartínP , AntoniniA , BrownR , FriedmanJ , OnofrjM , et al. Rotigotine and specific non‐motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism and Related Disorders2013;19:660‐5. ">Chaudhuri 2013</a>; <a href="./references#CD010925-bbs2-0039" title="JangW , ParkJ , ShinK , KimJ , KimJ , YounJ , et al. Safety and efficacy of recombinant human erythropoietin treatment of non‐motor symptoms in Parkinson's disease. Journal of the Neurological Sciences2014;337:47‐54. ">Jang 2014</a>) were excluded because the authors used the Non‐Motor Symptoms Scale (NMSS), a clinician‐rated instrument, to assess fatigue. We excluded one study report (<a href="./references#CD010925-bbs2-0069" title="StocchiF , The ADAGIO Investigators. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. European Journal of Neurology2014;21:357‐60. ">Stocchi 2014</a>) that summarised previously published results by Rascol and colleagues (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>). The results presented in the original publication (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>) however, are included in this systematic review. Other reasons for exclusion are summarised in the <a href="./references#CD010925-sec-0105" title="">Characteristics of excluded studies</a> table. </p> <section id="CD010925-sec-0072"> <h5 class="title">Studies awaiting classification and ongoing studies</h5> <p>The characteristics of two studies (<a href="./references#CD010925-bbs2-0077" title="PahwaR , TannerC , HauserR , SethiK , IsaacsonS , TruongD , et al. Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED study). Movement Disorders2015;30:788‐95. ">Pahwa 2015</a>; <a href="./references#CD010925-bbs2-0078" title="SmithK , EyalE , WeintraubD . Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study. JAMA Neurology2015;72:88‐95. ">Smith 2015</a>) are summarised in the <a href="./references#CD010925-sec-0106" title="">Characteristics of studies awaiting classification</a> table. Three ongoing studies (trial registration number <a href="./references#CD010925-bbs2-0079" title="Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicenter, randomised, double‐blind, placebo‐controlled study in parallel groups.. Ongoing studyFebruary 2008 (first enrollment).. ">EUCTR2007‐002195‐34‐FR</a>, <a href="./references#CD010925-bbs2-0080" title="Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease (REST).. Ongoing studyDecember 2009 (first enrollment).. ">NCT01168596</a> and <a href="./references#CD010925-bbs2-0081" title="Acupuncture for fatigue in Parkinson's disease.. Ongoing studyAugust 2010 (first enrollment).. ">NCT01360229</a>) were identified. Details on study design are presented in the <a href="./references#CD010925-sec-0107" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> </section> <section id="CD010925-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD010925-fig-0002">Figure 2</a> summarises the scores for the risk of bias assessment. A detailed description about the risk of bias in the included studies is presented in the <a href="./references#CD010925-sec-0104" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD010925-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010925-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Eight out of 11studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>; <a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>; <a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) used adequate methods for randomisation and allocation concealment. One study (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>) scored high risk for selection bias because allocation was not concealed. Two studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>) were not clear in describing randomisation and allocation concealment and scored unclear risk for selection bias. </p> <p>Except for one study (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>), all studies that investigated pharmacological interventions used matched‐placebo and therefore scored low risk for performance bias and detection bias for patient‐reported outcomes. One study (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>) did not describe blinding procedures for outcome assessors and scored unclear risk for detection bias for other outcomes. </p> <p>Since blinding of participants and study personnel is not possible in studies that investigate exercise interventions, two studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a> scored high risk for performance bias and detection bias for patient‐reported outcomes. Blinding procedures of outcome assessors were adequate; therefore, both studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) scored low risk for detection bias for other outcomes. </p> <p>One study (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) scored high risk for attrition bias as three participants (33%) in the intervention group dropped out because of an adverse effect related to study medication. Two studies (<a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>; <a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>) scored unclear risk for attrition bias because participants that were lost to follow up were not included in the statistical analyses. </p> </section> <section id="CD010925-sec-0074"> <h3 class="title" id="CD010925-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD010925-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings levodopa‐carbidopa</a>; <a href="./full#CD010925-tbl-0002"><b>Summary of findings 2</b> Summary of findings memantine</a>; <a href="./full#CD010925-tbl-0003"><b>Summary of findings 3</b> Summary of findings rasagiline</a>; <a href="./full#CD010925-tbl-0004"><b>Summary of findings 4</b> Summary of findings caffeine</a>; <a href="./full#CD010925-tbl-0005"><b>Summary of findings 5</b> Summary of findings methylphenidate</a>; <a href="./full#CD010925-tbl-0006"><b>Summary of findings 6</b> Summary of findings modafinil</a>; <a href="./full#CD010925-tbl-0007"><b>Summary of findings 7</b> Summary of findings doxepin</a>; <a href="./full#CD010925-tbl-0008"><b>Summary of findings 8</b> Summary of findings exercise</a> </p> <p>The main outcomes for each intervention and the quality of the evidence are summarised in the 'Summary of findings' tables (see <a href="./full#CD010925-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010925-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010925-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010925-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD010925-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD010925-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD010925-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD010925-tbl-0008">summary of findings Table 8</a>). </p> <p><b>Pharmacological interventions</b> </p> <p><b>Levodopa‐carbidopa</b> </p> <p>One study (<a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a>) investigated the effect of levodopa‐carbidopa on the impact of fatigue on ADL and fatigue severity. We combined the three intervention groups to create a single pair‐wise comparison for this study. After 42 weeks, no statistically significant difference was found between the combined levodopa‐carbidopa group and the placebo group (N = 340, SMD = ‐0.22, 95% CI ‐0.47 to 0.02). </p> <p><a href="#CD010925-tbl-0009">Table 1</a> summarises the risk of adverse effects. Levodopa‐carbidopa significantly increased the risk for nausea (N = 361, RR = 1.85, 95% CI 1.05 to 3.27). </p> <div class="table" id="CD010925-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of adverse effects for pharmacological interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk Ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Favours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Levodopa‐carbidopa versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.15 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66 (0.82 to 8.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.28 to 3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inconclusive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.85 (1.05 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Memantine versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 69.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14 (0.01 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Rasagiline versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.33 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.50 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.27 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.07 (0.13 to 75.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.49 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.15 to 2.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Caffeine versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.07 to 15.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.20 to 21.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Methylphenidate versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.01 to 4.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.00 (0.31 to 115.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.08 to 17.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.02 to 9.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Modafinil versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.14 (0.35 to 27.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.07 to 4.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.43 (0.16 to 71.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.11 to 8.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Doxepin versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> </tbody> </table> </div> <p><b>Memantine</b> </p> <p>Ondo and colleagues (<a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a>) investigated the effect of memantine on the impact of fatigue on ADL and fatigue severity. After eight weeks, no difference was found between memantine and placebo (N = 36, SMD = 0.10, 95% CI ‐0.56 to 0.75). </p> <p>No statistically significant differences were found for the risk of adverse effects (see <a href="#CD010925-tbl-0009">Table 1</a>). </p> <p>Memantine did not improve depression (N = 36, SMD = 0.15, 95% CI ‐0.51 to 0.81), HRQOL (N = 36, SMD = 0.38, 95% CI ‐0.29 to 1.04) or sleep disturbances (N = 36, SMD = 0.25, 95% CI ‐0.41 to 0.91). </p> <p><b>Rasagiline</b> </p> <p>Rascol and colleagues (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>) investigated the effect of rasagiline 1 mg/day and rasagiline 2 mg/day on the impact of physical fatigue on ADL. For the impact of physical fatigue on ADL, we were able to combine the two experimental groups in a meta‐analysis (see <a href="#CD010925-fig-0003">Figure 3</a>). After 36 weeks, a statistically significant difference was found between rasagiline and placebo. People that used rasagiline experienced significantly lower levels of physical fatigue when compared with people receiving placebo (N = 1176, SMD = ‐0.27, 95% CI ‐0.39 to ‐0.16, I<sup>2</sup> = 0%). Sensitivity analysis using a fixed‐effect model yielded the same result. </p> <div class="figure" id="CD010925-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rasagiline versus placebo, outcome: 1.1 Subjective impact of physical fatigue (post‐intervention)." data-id="CD010925-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rasagiline versus placebo, outcome: 1.1 Subjective impact of physical fatigue (post‐intervention). </p> </div> </div> </div> <p>We had to create a single pair‐wise comparison to calculate the risk of adverse effects. Rasagiline did not significantly increase the risk for adverse effects compared to placebo (see <a href="#CD010925-tbl-0009">Table 1</a>). </p> <p><b>Caffeine</b> </p> <p>One study (<a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a>) investigated the effect of caffeine on fatigue. After six weeks, no difference was found between caffeine and placebo on the impact of fatigue on ADL (N = 61, SMD = ‐0.29, 95% CI ‐0.79 to 0.22) and on fatigue severity (N = 61, SMD = 0.19, 95% CI ‐0.32 to 0.69). </p> <p>No statistically significant differences were found for the risk of adverse effects (see <a href="#CD010925-tbl-0009">Table 1</a>). </p> <p>Caffeine did not improve depression (N = 61, SMD = 0.14, 95% CI ‐0.36 to 0.65) and HRQOL (N = 61, SMD = ‐0.06, 95% CI ‐0.56 to 0.44). Two questionnaires were used to investigate the effect of caffeine on sleep disturbances; no differences were found between caffeine and placebo on the Epworth Sleepiness Scale (ESS) (N = 61, SMD = ‐0.46, 95% CI ‐0.96 to 0.05) and the Pittsburgh Sleep Quality Index (PSQI) (N = 61, SMD = ‐0.13, 95% CI ‐0.63 to 0.38). </p> <p><b>Methylphenidate</b> </p> <p>One study (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>) investigated the effect of methylphenidate on fatigue. Two self‐report questionnaires were used to measure fatigue. After six weeks no statistically significant differences were found between methylphenidate and placebo on the FSS (N = 34, SMD = ‐0.64, 95% CI ‐1.33 to 0.05) and the MFI total score (N = 34, SMD = ‐0.36, 95% CI ‐1.04 to 0.32). The MFI subscales were used to investigate the effect of methylphenidate on the impact of physical and mental fatigue on ADL. No statistically significant differences were found for physical fatigue (N = 34, SMD = ‐0.48, 95% CI ‐1.17 to 0.20) or mental fatigue (N = 34, SMD = 0.02, 95% CI ‐0.65 to 0.70). </p> <p>The risk of adverse effects did not significantly differ in people that used methylphenidate compared with people that received placebo (see <a href="#CD010925-tbl-0009">Table 1</a>). </p> <p><b>Modafinil</b> </p> <p>Three studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) investigated the effect of modafinil on the impact of fatigue on ADL. One study presented insufficient data (<a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>), the other two studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>) were pooled in a meta‐analysis (see <a href="#CD010925-fig-0004">Figure 4</a>). No statistically significant difference was found between modafinil and placebo (N = 53, SMD = ‐0.17, 95% CI ‐0.72 to 0.37, I<sup>2</sup> = 0%). The subgroup analysis presented in <a href="#CD010925-fig-0004">Figure 4</a> shows that the estimate of effect for modafinil in people with underlying depression was larger (N = 16, SMD = ‐0.40, 95% CI ‐1.43 to 0.62) compared to non‐depressed people (N = 37, SMD = ‐0.08, 95% CI ‐0.73 to 0.56). The robustness of the random‐effects model was confirmed by sensitivity analysis; meta‐analysis using a fixed effect model did not change the effect of modafinil. Sensitivity analysis in which we excluded one study because of unclear allocation concealment and high risk of attrition bias (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) reduced the effect size of modafinil (N = 37, SMD = ‐0.08, 95% CI ‐0.73 to 0.56). </p> <div class="figure" id="CD010925-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.1 Subjective impact of fatigue (post‐intervention)." data-id="CD010925-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.1 Subjective impact of fatigue (post‐intervention). </p> </div> </div> </div> <p>In one study (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>), post‐treatment data showed a statistically significant difference for the impact of physical fatigue on ADL between people that used modafinil and people that received placebo (N = 16, SMD = ‐1.23, 95% CI ‐2.36 to ‐0.11). No effect was found on the impact of mental fatigue on ADL (N = 16, SMD = 0.05, 95% CI ‐0.97 to 1.06). Another study (<a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>) investigated the effect of modafinil on fatigue severity; no statistically significant difference was found between modafinil and placebo (N = 37, SMD = ‐0.08, 95% CI ‐0.73 to 0.56). </p> <p><a href="#CD010925-tbl-0009">Table 1</a> summarises the risk of adverse effects in people that used modafinil compared with people that received placebo. The results of two studies (<a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a>) were pooled in a meta‐analysis; no statistically significant differences were found for anxiety (N = 50, RR = 3.14, 95% CI 0.35 to 27.79, I<sup>2</sup> = 0%) (<a href="#CD010925-fig-0005">Figure 5</a>) or nausea (N = 50, RR = 1.01, 95% CI 0.11 to 8.93, I<sup>2</sup> = 0%) (<a href="#CD010925-fig-0006">Figure 6</a>). Sensitivity analyses using fixed‐effect models showed comparable results (RR = 3.13, 95% CI 0.35 to 27.68, I<sup>2</sup> = 0% and RR = 1.04, 95% CI 0.15 to 7.21, I<sup>2</sup> = 0% respectively). </p> <div class="figure" id="CD010925-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.2 Anxiety (adverse event) (post‐intervention)." data-id="CD010925-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.2 Anxiety (adverse event) (post‐intervention). </p> </div> </div> </div> <div class="figure" id="CD010925-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.3 Nausea (adverse event) (post‐intervention)." data-id="CD010925-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.3 Nausea (adverse event) (post‐intervention). </p> </div> </div> </div> <p>Two studies (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>) investigated the effect of modafinil on depression and sleep disturbances. <a href="#CD010925-fig-0007">Figure 7</a> and <a href="#CD010925-fig-0008">Figure 8</a> present the results that were pooled in a meta‐analysis; no statistical differences were found for depression (N = 53, SMD = ‐0.12, 95% CI ‐0.67 to 0.42, I<sup>2</sup> = 0%) and sleep disturbances (N = 53, SMD = ‐0.31, 95% CI ‐0.86 to 0.24, I<sup>2</sup> = 0%). Subgroup analyses show that the estimates of effect for modafinil in people with underlying depression were larger compared to people without depressive disorders (see <a href="#CD010925-fig-0007">Figure 7</a> and <a href="#CD010925-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD010925-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.4 Depression (post‐intervention)." data-id="CD010925-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.4 Depression (post‐intervention).</p> </div> </div> </div> <div class="figure" id="CD010925-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.5 Sleep disturbances (post‐intervention)." data-id="CD010925-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.5 Sleep disturbances (post‐intervention). </p> </div> </div> </div> <p>The robustness of the random‐effects models was confirmed by sensitivity analysis; meta‐analyses using fixed effect models did not change the effects. Sensitivity analysis in which we excluded one study because of unclear allocation concealment and high risk of attrition bias (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) reduced the effect sizes of modafinil for depression (N = 37, SMD = ‐0.02, 95% CI ‐0.67 to 0.62) and sleep disturbances (N = 37, SMD = ‐0.20, 95% CI ‐0.85 to 0.44). </p> <p><b>Doxepin</b> </p> <p>One study (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>) investigated the effect of doxepin on fatigue. After six weeks, a statistically significant difference was found between doxepin and placebo on the impact of fatigue on ADL and fatigue severity (N = 12, SMD = ‐1.50, 95% CI ‐2.84 to ‐0.15). No statistically significant differences were found for the risk of adverse effects (see <a href="#CD010925-tbl-0009">Table 1</a>). </p> <p>Doxepin did not improve depression (N = 12, SMD = ‐0.24, 95% CI ‐1.38 to 0.89) and HRQOL (N = 12, SMD = ‐0.35, 95% CI ‐1.49 to 0.79). Several questionnaires were used to investigate the effect of doxepin on sleep disturbances; a statistically significant difference was found between doxepin and placebo on the Insomnia Severity Index (ISI) (N = 12, SMD = ‐1.37, 95% CI = ‐2.69 to ‐0.06) but not on the total‐scores of the other instruments used. </p> <p><b>Non‐pharmacological interventions</b> </p> <p><b>Exercise</b> </p> <p>Two studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) investigated the effect of an exercise programme on the impact of fatigue on ADL and fatigue severity. A meta‐analysis (<a href="#CD010925-fig-0009">Figure 9</a>) showed no statistically significant differences between exercise and usual care (N = 57, SMD = ‐0.45, 95% CI ‐1.21 to 0.32, I<sup>2</sup> = 44%). Sensitivity analyses using a fixed‐effect model yielded comparable results (SMD = ‐0.35, 95% CI ‐0.88 to 0.18, I<sup>2</sup> = 44%). </p> <div class="figure" id="CD010925-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.1 Subjective impact of fatigue and fatigue severity (post‐intervention)." data-id="CD010925-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.1 Subjective impact of fatigue and fatigue severity (post‐intervention). </p> </div> </div> </div> <p>One study (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>) investigated possible adverse effects related to the exercise program. No adverse effects related to treadmill training were reported, including any falls during training (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>). </p> <p><a href="#CD010925-fig-0010">Figure 10</a> presents the pooled results of two studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) that investigated the effect of exercise on HRQOL. No statistically significant differences between exercise and usual care were found (N = 57, SMD = ‐0.08, 95% CI ‐0.60 to 0.45, I<sup>2</sup> = 0%). Sensitivity analysis using a fixed effect model yielded the same results. </p> <div class="figure" id="CD010925-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.2 HRQOL (PDQ‐39) (post‐intervention)." data-id="CD010925-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.2 HRQOL (PDQ‐39) (post‐intervention). </p> </div> </div> </div> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010925-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010925-sec-0075"></div> <section id="CD010925-sec-0076"> <h3 class="title" id="CD010925-sec-0076">Summary of main results</h3> <p>The aim of the present systematic review was to evaluate the effect of pharmacological and non‐pharmacological interventions on subjective fatigue in people with PD. </p> <p>We included a total of eleven studies; three of these studies included only people who experienced clinically relevant fatigue, whereas all other studies did not select participants on the basis of experienced fatigue. Nine studies investigated the effect of medication (i.e. levodopa‐carbidopa, memantine, rasagiline, caffeine, methylphenidate, modafinil and doxepin) on subjective fatigue. Only doxepin significantly reduced the impact of fatigue on ADL and fatigue severity. Post‐treatment data showed statistically significant differences for the impact of physical fatigue, as measured by the PFS‐16 or the MFI physical fatigue subscale, between people that used rasagiline or modafinil compared with placebo. With regard to adverse effects, only levodopa‐carbidopa showed a statistically significant increase for the risk of nausea. </p> <p>Pooling the two studies that investigated the effect of exercise on subjective fatigue showed non‐significant reductions of the impact of fatigue on ADL or in terms of fatigue severity. </p> </section> <section id="CD010925-sec-0077"> <h3 class="title" id="CD010925-sec-0077">Overall completeness and applicability of evidence</h3> <p><b>Pharmacological interventions</b> </p> <p>Although our results suggest that doxepin significantly reduces the impact of fatigue on ADL and fatigue severity in people with PD, this finding has to be interpreted with care because the methodology used in the study by Rios Romenets and colleagues (<a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a>) shows some serious flaws. Firstly, allocation of participants to the experimental or control group was not concealed; and secondly, outcome assessment for patient‐reported outcomes was not blinded. Therefore, it is likely that the effect found was subject to substantial bias and therefore overestimated. </p> <p>One large study (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>) showed that rasagiline had a small but statistically significant effect on the impact of physical fatigue on ADL. The group that received rasagiline 2 mg/day scored 0.19 points lower on the PFS‐16, which represents 3.8% of the total score, compared with placebo. Participants that received rasagiline 1 mg/day scored on average 0.14 points (2.8% of total score) lower compared with placebo. These findings suggest that rasagiline may be an effective treatment to reduce symptoms of physical fatigue in people with PD. However, it is difficult to generalise these findings to clinical practice. First, the study was designed to investigate whether rasagiline had disease‐modifying effects in people with recently diagnosed PD (i.e. disease duration of 18 months or less from time of diagnosis). This limits the generalisability of results to people with more advanced PD. Second, participants that received placebo showed a significant worsening of fatigue over time, whereas participants receiving rasagiline mostly maintained baseline levels of fatigue (<a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a>). This suggests that rasagiline may reduce or slow down the progression of physical fatigue over time; however, it remains unclear if rasagiline is able to reduce the actual levels of physical fatigue in people with PD. Preliminary results of an ongoing study (<a href="./references#CD010925-bbs2-0080" title="Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease (REST).. Ongoing studyDecember 2009 (first enrollment).. ">NCT01168596</a>) showed that rasagiline 1 mg/day did not significantly reduce the impact of fatigue on ADL in moderately to severely fatigued people with PD (<a href="./references#CD010925-bbs2-0045" title="LimT , KlugerB , RodriguezR , PalacioR , GuiratiY , NutterB , et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease: a 3‐center, placebo‐controlled, pilot study (the REST trial). Movement Disorders2013;28:S165. ">Lim 2013</a>). Further studies are needed to investigate whether rasagiline reduces actual levels of physical fatigue in people with PD. </p> <p>Our results also suggest that modafinil significantly reduces the impact of physical fatigue on ADL (N = 16, SMD = ‐1.23, 95% CI ‐2.36 to ‐0.11). This finding is in conflict with the original study (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) in which the authors concluded that modafinil did not improve subjective fatigue in people with PD. The difference found between modafinil and placebo at the end of the treatment period is likely biased by a generated imbalance at baseline. Although not statistically significant, participants that were allocated to the modafinil group reported lower physical fatigue at baseline compared with participants that were allocated to the placebo group. Lou and colleagues (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) used a mixed model that took into account both between‐ and within‐patient variances, which probably yields a more valid result than our standard post‐treatment analysis. With that, it is more likely to conclude that modafinil does not significantly reduce the impact of physical fatigue on ADL. </p> <p>Although no safety issues with regard to adverse effect were identified in the studies included in our systematic review, concerns have been raised that long‐term use of psychostimulants (e.g. methylphenidate and modafinil) might cause drug dependency, psychotic symptoms and behavioural sensitisation similar to other stimulants (<a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>). Rare cases of serious or life‐threatening skin conditions have been reported in people using modafinil (<a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>). Two 'evidence‐based medicine reviews' about treatments for motor and non‐motor symptoms of PD (<a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>; <a href="./references#CD010925-bbs2-0089" title="FoxS , KatzenschlagerR , LimS , RavinaB , SeppiK , CoelhoM , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the motor symptoms of Parkinson's disease. Movement Disorders2011;26:S2‐S41. ">Fox 2011</a>) concluded that the safety of levodopa‐carbidopa, memantine and rasagiline is acceptable. Another systematic review (<a href="./references#CD010925-bbs2-0094" title="FrisinaP , TenenbaumH , BorodJ . The effects of antidepressants in Parkinson’s disease: a meta‐analysis. International Journal of Neuroscience2008;118:667‐82. ">Frisina 2008</a>) concluded that tricyclic antidepressants, such as doxepin, could be used in people with PD without the risk of substantial side effects. </p> <p><b>Non‐pharmacological interventions</b> </p> <p>Meta‐analysis of two studies (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) showed that exercise did not significantly affect the impact of fatigue on ADL and fatigue severity in people with PD. Although both studies focused on the improvement of exercise capacity, the studies differed strongly in the achieved intensity of performed exercise. Canning and colleagues (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>) planned four treadmill‐training sessions a week for six weeks. Participants in this study showed excellent adherence and completed on average 94% of the prescribed sessions (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>). In the other study (<a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>) participants were encouraged to attend five aerobic sessions and two strength sessions per week for a period of 12 weeks; however, in this study participants self‐determined the number of sessions they attended, which was low. Only 11 out of 20 people achieved weekly attendance (<a href="./references#CD010925-bbs2-0011" title="WinwardC , SackleyC , MeekC , IzadiH , BarkerK , WadeD , et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders2012;27:143‐6. ">Winward 2012</a>). The difference in adherence to the programme, and thus exercise intensity, may explain the difference in the magnitude of effect between both studies. Specific prescribed intensity (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>) seems to improve the effect of an exercise programme; however, this finding has to be confirmed in future studies. </p> <p>Despite our broad search strategy, we identified no studies that investigated the effect of cognitive behavioural therapy or other non‐pharmacological interventions on subjective fatigue in people with PD. </p> <p><b>General issues in studying interventions for fatigue in PD</b> </p> <p>Most studies included in our systematic review did not select participants on the basis of fatigue severity. As a result, mean baseline levels of fatigue in these studies just reached the cut‐off point for clinically relevant fatigue. This may have contributed to the lack of effect for most interventions included in this systematic review and one may argue that interventions may be more beneficial in more severely fatigued people. </p> <p>Since fatigue is one of the criterion symptoms for a major depressive disorder (<a href="./references#CD010925-bbs2-0083" title="American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th Edition. Arlington: American Psychiatric Association, 2013. ">APA 2013</a>) and depression may overlap with or exacerbate feelings of subjective fatigue (<a href="./references#CD010925-bbs2-0099" title="HerlofsonK , OngreS , EngerL , Tysnes , O , Larsen , J . Fatigue in early Parkinson's disease. Minor inconvenience or major distress?. European Journal of Neurology2012;19:963‐8. ">Herlofson 2012</a>), it is possible that people with depressive disorders respond differently to treatment for fatigue than non‐depressed people. Our subgroup analysis showed a trend that modafinil was more effective in depressed people than in people without underlying depression; however, this result has to be interpreted with caution. First, the found effects in both subgroups were not statistically significant. Second, the subgroup analysis consisted of only two studies of which one (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) scored high risk for attrition bias, which may have resulted in an overestimation of the effect of modafinil in people with depressive disorders. </p> <p>Previous research (<a href="./references#CD010925-bbs2-0104" title="LouJ , KearnsG , OkenB , SextonG , NuttJ . Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Movement Disorders2001;16:190‐6. ">Lou 2001</a>) suggested that physical fatigue and mental fatigue may have different aetiologies and therefore may need to be managed separately. Two studies that investigated the effect of psychostimulants on physical fatigue and mental fatigue (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>; <a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>) showed a trend towards more improvement on the impact of physical fatigue than on the impact of mental fatigue on ADL. Improvements were small and not statistically significant; however, these findings may support the hypothesis that physical fatigue and mental fatigue are independent symptoms that have to be treated differently. Unfortunately, we were not able to test this hypothesis in subgroup analyses because only one study (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) in our meta‐analyses provided data on baseline levels of perceived physical and mental fatigue. </p> <p>Although most studies used validated self‐report questionnaires to measure fatigue, the interpretation of the magnitude of effect is difficult as measurement properties such as measurement error and responsiveness have not yet been investigated properly in people with PD (<a href="./references#CD010925-bbs2-0087" title="ElbersR , RietbergM , VanWegenE , VerhoefJ , KramerS , TerweeC , et al. Self‐report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Quality of Life Research2012;21:925‐44. ">Elbers 2012a</a>). It is unclear whether measurement error and responsiveness of the self‐report questionnaires is adequate to detect clinically meaningful changes in subjective fatigue. For example, the found effect of modafinil (<a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>) and methylphenidate (<a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a>) on the impact of fatigue measured by the MFI did not exceed the smallest detectable change (i.e. the measurement error) of this instrument in people with PD (<a href="./references#CD010925-bbs2-0088" title="ElbersR , VanWegenE , VerhoefJ , KwakkelG . Reliability and structural validity of the multidimensional fatigue inventory in patients with idiopathic Parkinson’s disease. Parkinsonism and Related Disorders2012;18:532‐6. ">Elbers 2012b</a>). Furthermore, different questionnaires measure different aspects or constructs of fatigue (<a href="./references#CD010925-bbs2-0087" title="ElbersR , RietbergM , VanWegenE , VerhoefJ , KramerS , TerweeC , et al. Self‐report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Quality of Life Research2012;21:925‐44. ">Elbers 2012a</a>), which makes it difficult to compare results between studies. </p> </section> <section id="CD010925-sec-0078"> <h3 class="title" id="CD010925-sec-0078">Quality of the evidence</h3> <p>We rated the effect of rasagiline on the impact of physical fatigue on ADL as high quality evidence. With regard to adverse effects, we found high quality evidence that levodopa‐carbidopa increased the risk for nausea as a drug‐related adverse effect. However, designating a single RCT as high quality evidence may feel uncomfortable, given that initial positive study results do often not hold up under subsequent investigation (<a href="./references#CD010925-bbs2-0095" title="GuyattG , OxmanA , VistG , KunzR , BrozekJ , Alonson‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64:407‐15. ">Guyatt 2011</a>). Although it is not currently possible to investigate consistency for these results, automatically downgrading quality is not recommended by the GRADE working group (<a href="./references#CD010925-bbs2-0095" title="GuyattG , OxmanA , VistG , KunzR , BrozekJ , Alonson‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64:407‐15. ">Guyatt 2011</a>). </p> <p>For most other outcomes, the quality of the evidence was rated ‘moderate‘ because of imprecision of results. This indicates that for these outcomes future research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate of effect. The quality of the evidence for the effect of modafinil and doxepin on the impact of fatigue on ADL ranged from low to very low. Therefore, the evidence in favour of the effect of modafinil and doxepin on the impact of fatigue on ADL should be considered with caution, as further research is likely to change the estimate of effect. </p> </section> <section id="CD010925-sec-0079"> <h3 class="title" id="CD010925-sec-0079">Potential biases in the review process</h3> <p>This systematic review has some limitations. First, as studies used different self‐report questionnaires to assess fatigue, we transformed all continuous outcomes into SMD's. Unfortunately, the interpretation of the SMD is challenging as rules of thumb (<a href="./references#CD010925-bbs2-0085" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988. ">Cohen 1988</a>) are to a certain extent arbitrary and do not intuitively resonate with either clinicians or people with PD (<a href="./references#CD010925-bbs2-0102" title="JohnstonB , ThorlundK , SchünemannH , XieF , MuradM , MontoriV , et al. Improving the interpretation of quality of life evidence in meta‐analysis: the application of minimal important difference units. Health and Quality of Life Outcomes2010;8:116. ">Johnston 2010</a>). To address this limitation we planned to perform additional analyses in which we standardised continuous outcomes into minimal important difference (MID) units (<a href="./references#CD010925-bbs2-0108" title="ElbersRG , VerhoefJ , vanWegenEEH , BerendseHW , KwakkelG . Interventions for fatigue in Parkinson's disease. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010925] ">Elbers 2014</a>; <a href="./references#CD010925-bbs2-0102" title="JohnstonB , ThorlundK , SchünemannH , XieF , MuradM , MontoriV , et al. Improving the interpretation of quality of life evidence in meta‐analysis: the application of minimal important difference units. Health and Quality of Life Outcomes2010;8:116. ">Johnston 2010</a>) to indicate whether the observed effect is considered important by people with PD. However, despite an extensive literature search, we found established MID values for only a few questionnaires. Therefore we decided to perform analyses based on SMDs only. Second, for continuous outcomes we used post‐intervention data to calculate the mean difference between the intervention group and the control group (<a href="./references#CD010925-bbs2-0086" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). For two small studies, that included baseline measurements in their statistical analyses (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>), this method resulted in other estimates of effect compared to the data presented in the original publication. However, taking the clinical relevance of the effects and the quality of the evidence into account, our conclusions are largely in line with the conclusions presented in the original publications (<a href="./references#CD010925-bbs2-0001" title="CanningC , AllenN , DeanC , GohL , FungV . Home‐based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation2012;26:817‐26. ">Canning 2012</a>; <a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a>). </p> </section> <section id="CD010925-sec-0080"> <h3 class="title" id="CD010925-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are in line with a previous review, <a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>. The review authors concluded that there was insufficient evidence either for, or against the effectiveness of methylphenidate and modafinil to treat subjective fatigue in people with PD (<a href="./references#CD010925-bbs2-0107" title="SeppiK , WeintraubD , CoelhoM , Perez‐LloretS , FoxS , KatzenschlagerR , et al. The Movement Discorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease. Movement Disorders2011;26:S42‐S80. ">Seppi 2011</a>). Recently, Franssen and colleagues (<a href="./references#CD010925-bbs2-0090" title="FranssenM , WinwardC , ColletJ , WadeD , DawesH . Interventions for fatigue in Parkinson's disease: a systematic review and meta‐analysis. Movement Disorders2014;29:1675‐8. ">Franssen 2014</a>) systematically reviewed the effects of pharmacological and non‐pharmacological interventions on fatigue in people with PD. All studies included in their systematic review were identified by our search strategy and considered for inclusion. However, we used slightly different criteria for study selection and excluded four studies (<a href="./references#CD010925-bbs2-0012" title="AbeK , TakanashiM , YanagiharaT , SakodaS . Pergolide mesilate may improve fatigue in patients with Parkinson's disease. Behavioural Neurology2001;13:117‐21. ">Abe 2001</a>; <a href="./references#CD010925-bbs2-0030" title="DrijgersR , VerheyF , TissinghG , vanDomburgP , AaltenP , LeentjensA . The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo controlled experimental challenge with pramipexole and methylphenidate. Journal of the Neurological Sciences2012;320:121‐6. ">Drijgers 2012</a>; <a href="./references#CD010925-bbs2-0033" title="GhahariS , PackerT , PassmoreA . Effectiveness of an online fatigue self‐management programme for people with chronic neurological conditions: a randomized controlled trial. Clinical Rehabilitation2010;24:727‐44. ">Ghahari 2010</a>; <a href="./references#CD010925-bbs2-0043" title="LeentjensA , ScholtissenB , VreelingF , VerheyF . The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology2006;31:1009‐15. ">Leentjens 2006</a>) that were incorporated in their review. Nevertheless, our conclusions are in agreement with their findings as the authors concluded that insufficient evidence exists to support pharmacological or non‐pharmacological treatment of fatigue in people with PD. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010925-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010925-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010925-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rasagiline versus placebo, outcome: 1.1 Subjective impact of physical fatigue (post‐intervention)." data-id="CD010925-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rasagiline versus placebo, outcome: 1.1 Subjective impact of physical fatigue (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.1 Subjective impact of fatigue (post‐intervention)." data-id="CD010925-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.1 Subjective impact of fatigue (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.2 Anxiety (adverse event) (post‐intervention)." data-id="CD010925-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.2 Anxiety (adverse event) (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.3 Nausea (adverse event) (post‐intervention)." data-id="CD010925-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.3 Nausea (adverse event) (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.4 Depression (post‐intervention)." data-id="CD010925-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.4 Depression (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.5 Sleep disturbances (post‐intervention)." data-id="CD010925-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Modafinil versus placebo, outcome: 2.5 Sleep disturbances (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.1 Subjective impact of fatigue and fatigue severity (post‐intervention)." data-id="CD010925-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.1 Subjective impact of fatigue and fatigue severity (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.2 HRQOL (PDQ‐39) (post‐intervention)." data-id="CD010925-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Exercise versus usual care, outcome: 3.2 HRQOL (PDQ‐39) (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rasagiline versus placebo, Outcome 1 Subjective impact of physical fatigue (post‐intervention)." data-id="CD010925-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Rasagiline versus placebo, Outcome 1 Subjective impact of physical fatigue (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil versus placebo, Outcome 1 Subjective impact of fatigue (post‐intervention)." data-id="CD010925-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Modafinil versus placebo, Outcome 1 Subjective impact of fatigue (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil versus placebo, Outcome 2 Anxiety (adverse event) (post‐intervention)." data-id="CD010925-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Modafinil versus placebo, Outcome 2 Anxiety (adverse event) (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-002-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil versus placebo, Outcome 3 Nausea (adverse event) (post‐intervention)." data-id="CD010925-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Modafinil versus placebo, Outcome 3 Nausea (adverse event) (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-002-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil versus placebo, Outcome 4 Depression (post‐intervention)." data-id="CD010925-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Modafinil versus placebo, Outcome 4 Depression (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-002-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil versus placebo, Outcome 5 Sleep disturbances (post‐intervention)." data-id="CD010925-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Modafinil versus placebo, Outcome 5 Sleep disturbances (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Exercise versus usual care, Outcome 1 Subjective impact of fatigue and fatigue severity (post‐intervention)." data-id="CD010925-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Exercise versus usual care, Outcome 1 Subjective impact of fatigue and fatigue severity (post‐intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010925-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/urn:x-wiley:14651858:media:CD010925:CD010925-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_t/tCD010925-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Exercise versus usual care, Outcome 2 HRQOL (PDQ‐39) (post‐intervention)." data-id="CD010925-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Exercise versus usual care, Outcome 2 HRQOL (PDQ‐39) (post‐intervention).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/media/CDSR/CD010925/image_n/nCD010925-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings levodopa‐carbidopa</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levodopa‐carbidopa compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinical, Northern America</b> </p> <p><b>Intervention: levodopa‐carbidopa</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>levodopa‐carbidopa</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean impact of fatigue and fatigue severity in the intervention group was 0.22 standard deviations lower (‐0.47 to 0.02). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>340 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours levodopa‐carbidopa.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>26 per 1000 (8 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.46</p> <p>(0.15 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does not increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect,post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>89 per 1000 (27 to 287)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.66</p> <p>(0.82 to 8.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000 (9 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00</p> <p>(0.28 to 3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does not increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>247 per 1000</p> <p>(140 to 436)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.85</p> <p>(1.05 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa does increase risk for nausea.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings levodopa‐carbidopa</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings memantine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Memantine compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinical, Northern America</b> </p> <p><b>Intervention: memantine</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>memantine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.10 standard deviations higher (‐0.56 to 0.75). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000 (0 to 386)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does not increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000 (0 to 386)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does not increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000 (0 to 180)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00</p> <p>(0.13 to 69.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does increase risk for impulse control disorders.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>21 per 1000 (1 to 390)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.14</p> <p>(0.01 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine does not increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean HRQOL in the intervention group was 0.38 standard deviations lower</p> <p>(‐0.29 to 1.04).<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours placebo.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> <p><sup>c</sup>Positive SMD (0.38) in results section indicates worse HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings memantine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings rasagiline</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rasagiline compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinical, Europe and Northern America</b> </p> <p><b>Intervention: rasagiline</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>rasagiline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of physical fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of physical fatigue in the intervention group was 0.27 standard deviations lower (‐0.39 to ‐0.16). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, 2 independent comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours rasagiline.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000 (19 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.57</p> <p>(0.33 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for anxiety.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000 (31 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.80</p> <p>(0.50 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000 (10 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53</p> <p>(0.27 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 1000 (0 to 10)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.07</p> <p>(0.13 to 75.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for impulse control disorders.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 per 1000 (19 to 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.89</p> <p>(0.49 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000 (1 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.61</p> <p>(0.15 to 2.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176 (1 study, single pair‐wise comparison)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline does not increase risk for orthostatic hypotension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings rasagiline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings caffeine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Caffeine compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Northern America</b> </p> <p><b>Intervention: caffeine</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>caffeine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.29 standard deviations lower (‐0.79 to 0.22). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours caffeine.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective fatigue severity in the intervention group was 0.19 standard deviations lower (‐0.32 to 0.69). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000 (2 to 509)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.03</p> <p>(0.07 to 15.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caffeine does increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>67 per 1000 (6 to 697)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.07</p> <p>(0.20 to 21.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caffeine does increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean HRQOL in the intervention group was 0.06 standard deviations higher (‐0.56 to 0.44).<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Negative SMD (‐0.06) in results section indicates better HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings caffeine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings methylphenidate</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methylphenidate compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Northern America</b> </p> <p><b>Intervention: methylphenidate</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>methylphenidate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.64 standard deviations lower (‐1.33 to 0.05). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate effect favours methylphenidate.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of physical fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of physical fatigue in the intervention group was 0.48 standard deviations lower (‐1.17 to 0.20). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours methylphenidate.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of mental fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of mental fatigue in the intervention group was 0.02 standard deviations higher (‐0.65 to 0.70). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>118 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>28 per 1000 (1 to 544)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.24</p> <p>(0.01 to 4.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does not increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>140 per 1000 (0 to 350)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.00</p> <p>(0.31 to 115.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>71 per 1000</p> <p>(5 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.21</p> <p>(0.08 to 17.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>24 per 1000 (1 to 536)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.40</p> <p>(0.02 to 9.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate does not increase risk for tachycardia.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings methylphenidate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings modafinil</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Modafinil compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Europe and Northern America</b> </p> <p><b>Intervention: modafinil</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>modafinil</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.17 standard deviations lower (‐0.72 to 0.37). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of physical fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of physical fatigue in the intervention group was 1.23 standard deviations lower (‐2.36 to ‐0.11). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large effect favours modafinil.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of mental fatigue on ADL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of mental fatigue in the intervention group was 0.05 standard deviations higher (‐0.97 to 1.06). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective fatigue severity in the intervention group was 0.08 standard deviations lower (‐0.73 to 0.56). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000 (0 to 190)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.14</p> <p>(0.35 to 27.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does increase risk for anxiety.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>286 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>166 per 1000</p> <p>(20 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.58</p> <p>(0.07 to 4.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does not increase risk for headache.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>170 per 1000 (0 to 510)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.43</p> <p>(0.16 to 71.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does increase risk for hypertension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000</p> <p>Moderate</p> <p>71 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000 (4 to 357)</p> <p>72 per 1000 (8 to 634)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01</p> <p>(0.11 to 8.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil does increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence by one level because <a href="./references#CD010925-bbs2-0002" title="LouJ , DimitrovaD , ParkB , JohnsonS , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double‐blind, placebo‐controlled pilot study. Clinical Neuropharmacology2009;32:305‐10. ">Lou 2009</a> scored ‘unclear risk’ for selection bias and ‘high risk’ for attrition bias. </p> <p><sup>b</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>c</sup>We downgraded the quality of the evidence by two levels because the estimate of effect is likely biased by imbalance at baseline. </p> <p><sup>d</sup>Absolute effect derived from risk difference (RD). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings modafinil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings doxepin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxepin compared with placebo for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: clinic, Northern America</b> </p> <p><b>Intervention: doxepin</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>doxepin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean in subjective impact of fatigue in the intervention group was 1.50 standard deviations lower (‐2.84 to ‐0.15). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large effect favours doxepin.</p> <p>Statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> <p>(adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>170 per 1000 (0 to 530)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00</p> <p>(0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxepin does increase risk for nausea.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension (adverse effect, post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>170 per 1000 (0 to 530)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00</p> <p>(0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxepin does increase risk for orthostatic hypotension.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The change in mean HRQOL in the intervention group was 0.35 standard deviations higher (‐1.49 to 0.79).<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours doxepin.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of the evidence by two levels because <a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a> scored ‘high risk’ for selection bias, ‘high risk’ for performance bias and ‘high risk’ for detection bias. </p> <p><sup>b</sup>Absolute effect derived from risk difference (RD). </p> <p><sup>c</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>d</sup>Negative SMD (‐0.35) in results section indicates better HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings doxepin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010925-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings exercise</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Exercise compared with usual care for fatigue in Parkinson's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: people with Parkinson's disease</b> </p> <p><b>Settings: community, Australia, Europe</b> </p> <p><b>Intervention: exercise</b> </p> <p><b>Comparison: usual care</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>usual care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>exercise</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective impact of fatigue on ADL, fatigue severity (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean subjective impact of fatigue in the intervention group was 0.45 standard deviations lower (‐1.21 to 0.32). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small effect favours exercise.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (post‐intervention)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean HRQOL in the intervention group was 0.08 standard deviations higher (‐0.60 to 0.45).<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect.</p> <p>Not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of the evidence by one level because blinding for assessment of fatigue (patient‐reported) not possible. </p> <p><sup>b</sup>We downgraded the quality of evidence by one level due to imprecision of result. </p> <p><sup>c</sup>Negative SMD (‐0.08) in results section indicates better HRQOL score on PDQ‐39. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings exercise</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010925-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of adverse effects for pharmacological interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk Ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Favours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Levodopa‐carbidopa versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.15 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levodopa‐carbidopa</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66 (0.82 to 8.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.28 to 3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inconclusive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0009" title="SchifittoG , FriedmanJ , OakesD , ShulmanL , ComellaC , MarekK , et al. Fatigue in levodopa‐naïve subjects with Parkinson disease. Neurology2008;71:481‐5. ">Schifitto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.85 (1.05 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Memantine versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.01 to 7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 69.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0005" title="OndoW , ShinawiL , DavidsonA , LaiD . Memantine for non‐motor features of Parkinson's disease: a double‐blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders2011;17:156‐9. ">Ondo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14 (0.01 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memantine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Rasagiline versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.33 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.50 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.27 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impulse control disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.07 (0.13 to 75.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.49 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0007" title="RascolO , Fitzer‐AttasC , HauserR , JankovicJ , LangA , LangstonJ , et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analysis of the need for additional therapies, change in UPDRS scores, and non‐motor outcomes. Lancet Neurology2011;10:415‐23. ">Rascol 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.15 to 2.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasagiline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Caffeine versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.07 to 15.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0006" title="PostumaR , LangA , MunhozR , CharlandK , PelletierA , MoscovichM , et al. Caffeine for treatment of Parkinson disease. Neurology2012;79:651‐9. ">Postuma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.20 to 21.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Methylphenidate versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.01 to 4.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.00 (0.31 to 115.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.08 to 17.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0003" title="MendonçaD , MenezesK , JogM . Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders2007;22:2070‐6. ">Mendonça 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.02 to 9.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Modafinil versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.14 (0.35 to 27.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.07 to 4.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modafinil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.43 (0.16 to 71.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0004" title="OndoW , FayleR , AtassiF , JankovicJ . Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry2005;76:1636‐9. ">Ondo 2005</a>; <a href="./references#CD010925-bbs2-0010" title="TyneH , TaylorJ , BakerG , SteigerM . Modafinil for Parkinson's disease fatigue. Journal of Neurology2010;257:452‐6. ">Tyne 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.11 to 8.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Doxepin versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010925-bbs2-0008" title="Rios RomenetsS , CretiL , FichtenC , BailesS , LibmanE , PelletierA , et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism and Related Disorders2013;19:670‐5. ">Rios Romenets 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.15 to 61.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of adverse effects for pharmacological interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/full#CD010925-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010925-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rasagiline versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subjective impact of physical fatigue (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.39, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Experimental group I (Rasagiline 1 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.39, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Experimental group II (Rasagiline 2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.48, ‐0.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rasagiline versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010925-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Modafinil versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subjective impact of fatigue (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.72, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Depressed patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.43, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Non‐depressed patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.73, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety (adverse event) (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.35, 27.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Nausea (adverse event) (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.11, 8.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Depression (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.67, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Depressed patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.39, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Non‐depressed patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.67, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sleep disturbances (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.86, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Depressed patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.64, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Non‐depressed patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.85, 0.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Modafinil versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010925-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Exercise versus usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subjective impact of fatigue and fatigue severity (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐1.21, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HRQOL (PDQ‐39) (post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.60, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Exercise versus usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010925.pub2/references#CD010925-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010925.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010925-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010925-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010925-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010925-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010925-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010925-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010925-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="ta#CD010925-note-0005">தமிழ்</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010925\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010925\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010925\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010925\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010925\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010925.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010925.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010925.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010925.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010925.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726238603"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010925.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726238607"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010925.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8ec85a52f431',t:'MTc0MDcyNjIzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 